NO310473B1 - Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid - Google Patents
Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid Download PDFInfo
- Publication number
- NO310473B1 NO310473B1 NO19912385A NO912385A NO310473B1 NO 310473 B1 NO310473 B1 NO 310473B1 NO 19912385 A NO19912385 A NO 19912385A NO 912385 A NO912385 A NO 912385A NO 310473 B1 NO310473 B1 NO 310473B1
- Authority
- NO
- Norway
- Prior art keywords
- immunoglobulin
- human
- amino acid
- cdr
- humanized
- Prior art date
Links
- 108060003951 Immunoglobulin Proteins 0.000 title claims abstract description 133
- 102000018358 immunoglobulin Human genes 0.000 title claims abstract description 133
- 238000000034 method Methods 0.000 title claims description 40
- 108091033319 polynucleotide Proteins 0.000 title claims description 14
- 102000040430 polynucleotide Human genes 0.000 title claims description 14
- 239000002157 polynucleotide Substances 0.000 title claims description 14
- 238000002360 preparation method Methods 0.000 title description 3
- 150000001413 amino acids Chemical class 0.000 claims abstract description 93
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract description 36
- 230000027455 binding Effects 0.000 claims abstract description 32
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 31
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 claims abstract description 22
- 108010002350 Interleukin-2 Proteins 0.000 claims abstract description 13
- 102000000588 Interleukin-2 Human genes 0.000 claims abstract description 13
- 102000055277 human IL2 Human genes 0.000 claims abstract description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 24
- 239000000427 antigen Substances 0.000 claims description 19
- 108091007433 antigens Proteins 0.000 claims description 19
- 102000036639 antigens Human genes 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 238000006467 substitution reaction Methods 0.000 claims description 10
- 230000003993 interaction Effects 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 238000002955 isolation Methods 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract description 18
- 102000005962 receptors Human genes 0.000 abstract description 5
- 108020003175 receptors Proteins 0.000 abstract description 5
- 150000007523 nucleic acids Chemical class 0.000 abstract description 3
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 241001529936 Murinae Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 68
- 229940072221 immunoglobulins Drugs 0.000 description 29
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- 108091034117 Oligonucleotide Proteins 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 20
- 239000000370 acceptor Substances 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 16
- 201000010099 disease Diseases 0.000 description 14
- 239000012634 fragment Substances 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 12
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 238000010561 standard procedure Methods 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- 239000013598 vector Substances 0.000 description 9
- 108020004414 DNA Proteins 0.000 description 8
- 229940127089 cytotoxic agent Drugs 0.000 description 8
- 239000002596 immunotoxin Substances 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000002637 immunotoxin Effects 0.000 description 7
- 229940051026 immunotoxin Drugs 0.000 description 7
- 231100000608 immunotoxin Toxicity 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002254 cytotoxic agent Substances 0.000 description 6
- 231100000599 cytotoxic agent Toxicity 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 108090001008 Avidin Proteins 0.000 description 4
- 241000283707 Capra Species 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108010039491 Ricin Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011651 chromium Substances 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000000389 T-cell leukemia Diseases 0.000 description 2
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000008365 aqueous carrier Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 241000701822 Bovine papillomavirus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 108090000204 Dipeptidase 1 Proteins 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241000157426 Pernis Species 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 102000011755 Phosphoglycerate Kinase Human genes 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241001474728 Satyrodes eurydice Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101001099217 Thermotoga maritima (strain ATCC 43589 / DSM 3109 / JCM 10099 / NBRC 100826 / MSB8) Triosephosphate isomerase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 102000006635 beta-lactamase Human genes 0.000 description 1
- 239000003139 biocide Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- JCXGWMGPZLAOME-AKLPVKDBSA-N bismuth-212 Chemical compound [212Bi] JCXGWMGPZLAOME-AKLPVKDBSA-N 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000013611 chromosomal DNA Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- -1 etc. Substances 0.000 description 1
- 235000019000 fluorine Nutrition 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 1
- 229940097277 hygromycin b Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 239000011654 magnesium acetate Substances 0.000 description 1
- 235000011285 magnesium acetate Nutrition 0.000 description 1
- 229940069446 magnesium acetate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229940002004 the magic bullet Drugs 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- PIEPQKCYPFFYMG-UHFFFAOYSA-N tris acetate Chemical compound CC(O)=O.OCC(N)(CO)CO PIEPQKCYPFFYMG-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/087—Herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/085—Herpetoviridae, e.g. pseudorabies virus, Epstein-Barr virus
- C07K16/088—Varicella-zoster virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Virology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29097588A | 1988-12-28 | 1988-12-28 | |
US31025289A | 1989-02-13 | 1989-02-13 | |
PCT/US1989/005857 WO1990007861A1 (fr) | 1988-12-28 | 1989-12-28 | IMMUNOGLOBULINES CHIMERIQUES SPECIFIQUES CONTRE LA PROTEINE TAC p55 DU RECEPTEUR D'IL-2 |
Publications (3)
Publication Number | Publication Date |
---|---|
NO912385D0 NO912385D0 (no) | 1991-06-19 |
NO912385L NO912385L (no) | 1991-06-19 |
NO310473B1 true NO310473B1 (no) | 2001-07-09 |
Family
ID=26966505
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19912385A NO310473B1 (no) | 1988-12-28 | 1991-06-19 | Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid |
NO2001024C NO2001024I1 (no) | 1988-12-28 | 2001-12-17 | Trastuzumab eller farmasøytiske akseptable salter derav |
NO2001026C NO2001026I2 (no) | 1988-12-28 | 2001-12-17 | Daclizumab |
NO2001025C NO2001025I2 (no) | 1988-12-28 | 2001-12-17 | Palivizumab |
NO2005005C NO2005005I2 (no) | 1988-12-28 | 2005-02-18 | Bevacizumab eller farmasoeytisk akseptable salter derav |
NO2005026C NO2005026I2 (no) | 1988-12-28 | 2005-12-07 | Omalizumab eller farmasoeytisk akseptable salter derav |
NO2006009C NO2006009I2 (no) | 1988-12-28 | 2006-08-07 | Natalizumab eller farmasoytisk akseptable salter derav |
NO2007006C NO2007006I2 (no) | 1988-12-28 | 2007-04-18 | Ranibizumab eller farmasoytisk akseptable salter derav |
NO2009026C NO2009026I1 (no) | 1988-12-28 | 2009-11-12 | Certolizumab pegol |
Family Applications After (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2001024C NO2001024I1 (no) | 1988-12-28 | 2001-12-17 | Trastuzumab eller farmasøytiske akseptable salter derav |
NO2001026C NO2001026I2 (no) | 1988-12-28 | 2001-12-17 | Daclizumab |
NO2001025C NO2001025I2 (no) | 1988-12-28 | 2001-12-17 | Palivizumab |
NO2005005C NO2005005I2 (no) | 1988-12-28 | 2005-02-18 | Bevacizumab eller farmasoeytisk akseptable salter derav |
NO2005026C NO2005026I2 (no) | 1988-12-28 | 2005-12-07 | Omalizumab eller farmasoeytisk akseptable salter derav |
NO2006009C NO2006009I2 (no) | 1988-12-28 | 2006-08-07 | Natalizumab eller farmasoytisk akseptable salter derav |
NO2007006C NO2007006I2 (no) | 1988-12-28 | 2007-04-18 | Ranibizumab eller farmasoytisk akseptable salter derav |
NO2009026C NO2009026I1 (no) | 1988-12-28 | 2009-11-12 | Certolizumab pegol |
Country Status (32)
Country | Link |
---|---|
EP (6) | EP1491556B1 (fr) |
JP (6) | JP2828340B2 (fr) |
KR (1) | KR0178385B1 (fr) |
CN (1) | CN1057013C (fr) |
AT (2) | ATE133452T1 (fr) |
AU (1) | AU647383B2 (fr) |
BG (1) | BG61095B2 (fr) |
CA (2) | CA2006865C (fr) |
CZ (1) | CZ418691A3 (fr) |
DD (1) | DD296964A5 (fr) |
DE (14) | DE04076439T1 (fr) |
DK (2) | DK119191A (fr) |
ES (5) | ES2492815T3 (fr) |
FI (1) | FI108797B (fr) |
FR (1) | FR14C0070I1 (fr) |
HK (1) | HK1014718A1 (fr) |
HR (1) | HRP920500B1 (fr) |
HU (1) | HU211174A9 (fr) |
IE (1) | IE20000331A1 (fr) |
IL (2) | IL162181A (fr) |
LU (8) | LU90411I2 (fr) |
MC (1) | MC2146A1 (fr) |
NL (8) | NL990020I2 (fr) |
NO (9) | NO310473B1 (fr) |
NZ (2) | NZ231984A (fr) |
PT (1) | PT92758B (fr) |
RU (1) | RU2126046C1 (fr) |
SG (1) | SG78258A1 (fr) |
SI (1) | SI8912489B (fr) |
WO (1) | WO1990007861A1 (fr) |
YU (1) | YU48700B (fr) |
ZA (1) | ZA899956B (fr) |
Families Citing this family (967)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5800815A (en) * | 1903-05-05 | 1998-09-01 | Cytel Corporation | Antibodies to P-selectin and their uses |
US5851526A (en) * | 1985-04-19 | 1998-12-22 | Ludwig Institute For Cancer Research | Methods of treating colon cancer utilizing tumor-specific antibodies |
US5449760A (en) * | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US7247453B1 (en) * | 1988-12-30 | 2007-07-24 | Oklahoma Medical Research Foundation | Calcium binding recombinant antibody against protein C |
DE3900534A1 (de) * | 1989-01-10 | 1990-07-12 | Boehringer Mannheim Gmbh | Diagnostischer nachweis unter verwendung von chimaeren antikoerpern |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US6750325B1 (en) | 1989-12-21 | 2004-06-15 | Celltech R&D Limited | CD3 specific recombinant antibody |
GR1001050B (el) * | 1990-01-09 | 1993-04-28 | Protein Design Labs Inc | Νεος il-2 υποδοχευς ιδιαζοντων ανθρωπινων ανοσοσφαιρινων. |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
GB9020282D0 (en) * | 1990-09-17 | 1990-10-31 | Gorman Scott D | Altered antibodies and their preparation |
US5858725A (en) * | 1990-10-10 | 1999-01-12 | Glaxo Wellcome Inc. | Preparation of chimaeric antibodies using the recombinant PCR strategy |
US5994510A (en) * | 1990-12-21 | 1999-11-30 | Celltech Therapeutics Limited | Recombinant antibodies specific for TNFα |
HU219537B (hu) * | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
IE920716A1 (en) * | 1991-03-07 | 1992-09-09 | Gen Hospital Corp | Redirection of cellular immunity by receptor chimeras |
JP3213314B2 (ja) * | 1991-04-05 | 2001-10-02 | ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン | 幹細胞因子レセプターに対するモノクローナル抗体 |
RU2139351C1 (ru) * | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
DE69233482T2 (de) * | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
WO1994004679A1 (fr) * | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Procede pour fabriquer des anticorps humanises |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9115010D0 (en) * | 1991-07-11 | 1991-08-28 | Wellcome Found | Antibody |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5756096A (en) * | 1991-07-25 | 1998-05-26 | Idec Pharmaceuticals Corporation | Recombinant antibodies for human therapy |
US5709860A (en) * | 1991-07-25 | 1998-01-20 | Idec Pharmaceuticals Corporation | Induction of cytotoxic T-lymphocyte responses |
HU220295B (hu) * | 1991-07-25 | 2001-11-28 | Idec Pharmaceuticals Corp. | Antigénkészítmények és ezek alkalmazása citotoxikus T-limfocita reakciók indukálására |
US6136310A (en) * | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
IE922437A1 (en) * | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US6329509B1 (en) * | 1991-08-14 | 2001-12-11 | Genentech, Inc. | Anti-IgE antibodies |
US6699472B2 (en) | 1991-08-14 | 2004-03-02 | Genentech, Inc. | Method of treating allergic disorders |
EP0528767B1 (fr) * | 1991-08-21 | 2000-01-12 | Novartis AG | Dérivés d'anticorps |
GB9120467D0 (en) * | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
JP3024311B2 (ja) * | 1991-10-03 | 2000-03-21 | 味の素株式会社 | Il−2受容体重鎖に結合するポリペプチド |
US5474771A (en) | 1991-11-15 | 1995-12-12 | The Trustees Of Columbia University In The City Of New York | Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same |
US7070777B1 (en) | 1991-11-15 | 2006-07-04 | The Trustees Of Columbia University In The City Of New York | Method for inhibiting inflammation with an antibody that binds the 5C8 protein |
US5817310A (en) | 1991-12-02 | 1998-10-06 | Cor Therapeutics, Inc. | Inhibitory immunoglobulin polypeptides to human PDGF beta receptor |
JPH05244982A (ja) * | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5766886A (en) * | 1991-12-13 | 1998-06-16 | Xoma Corporation | Modified antibody variable domains |
US5869619A (en) * | 1991-12-13 | 1999-02-09 | Xoma Corporation | Modified antibody variable domains |
US5777085A (en) * | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
EP0625200B1 (fr) * | 1992-02-06 | 2005-05-11 | Chiron Corporation | Proteine de liaison biosynthetique pour marqueur de cancer |
GB9203459D0 (en) * | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5387676A (en) * | 1992-03-11 | 1995-02-07 | Ciba Corning Diagnostics Corp. | MN gene and protein |
US6129914A (en) * | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
US6033667A (en) * | 1992-05-05 | 2000-03-07 | Cytel Corporation | Method for detecting the presence of P-selectin |
US5874082A (en) * | 1992-07-09 | 1999-02-23 | Chiron Corporation | Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation |
US5397703A (en) * | 1992-07-09 | 1995-03-14 | Cetus Oncology Corporation | Method for generation of antibodies to cell surface molecules |
US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
US5958708A (en) * | 1992-09-25 | 1999-09-28 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
US6066718A (en) * | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
GB9223377D0 (en) * | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
DE669986T1 (de) * | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung. |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
ATE196606T1 (de) | 1992-11-13 | 2000-10-15 | Idec Pharma Corp | Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma |
US5648267A (en) * | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5804187A (en) * | 1992-11-16 | 1998-09-08 | Cancer Research Fund Of Contra Costa | Modified antibodies with human milk fat globule specificity |
DK0678122T3 (da) | 1993-01-12 | 2000-03-06 | Biogen Inc | Rekombinante anti-VLA4 antistofmolekyler |
US5730979A (en) * | 1993-03-05 | 1998-03-24 | Universite Catholique Delouvain | LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation |
US5951983A (en) * | 1993-03-05 | 1999-09-14 | Universite Catholique De Louvain | Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies |
US5817311A (en) * | 1993-03-05 | 1998-10-06 | Universite Catholique De Louvain | Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies |
WO1994025067A1 (fr) * | 1993-05-04 | 1994-11-10 | Cytel Corporation | Anticorps diriges contre la selectine p et leurs utilisations |
WO1994028025A1 (fr) | 1993-05-28 | 1994-12-08 | The Scripps Research Institute | Procedes et compositions d'inhibition de l'activation des cellules induites par cd14 |
TW458985B (en) * | 1993-05-31 | 2001-10-11 | Chugai Pharmaceutical Co Ltd | Reconstructed human antibody against human interleukin-6 |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
AU695726B2 (en) * | 1993-09-07 | 1998-08-20 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5928904A (en) * | 1993-09-07 | 1999-07-27 | Smithkline Beecham Corporation | DNA encoding recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US5914110A (en) * | 1993-09-07 | 1999-06-22 | Smithkline Beecham Corporation | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
US20020193575A1 (en) | 1993-09-07 | 2002-12-19 | Smithkline Beecham P.L.C. | Recombinant IL4 antibodies useful in treatment of IL4 mediated disorders |
EP0729976A1 (fr) | 1993-11-19 | 1996-09-04 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre des cellules medulloblastomateuses humaines |
AU2185195A (en) * | 1993-11-30 | 1995-06-19 | Protein Design Labs, Inc. | Reperfusion therapy using antibodies to L-selectin |
GB9325182D0 (en) * | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
DK1759709T3 (da) * | 1994-01-25 | 2013-06-10 | Elan Pharm Inc | Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 |
US5840299A (en) * | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
EP0753065B1 (fr) | 1994-03-29 | 2003-05-14 | Celltech Therapeutics Limited | Anticorps contre la selectine e |
US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US5622701A (en) | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
USRE39548E1 (en) * | 1994-06-17 | 2007-04-03 | Celltech R&D Limited | Interleukin-5 specific recombinant antibodies |
GB9412230D0 (en) * | 1994-06-17 | 1994-08-10 | Celltech Ltd | Interleukin-5 specific recombiant antibodies |
US6048972A (en) * | 1994-07-13 | 2000-04-11 | Chugai Pharmaceutical Co., Ltd. | Recombinant materials for producing humanized anti-IL-8 antibodies |
DE4425115A1 (de) * | 1994-07-15 | 1996-01-18 | Boehringer Mannheim Gmbh | Verfahren zur Modifizierung der Stabilität von Antikörpern |
EP0696455A1 (fr) * | 1994-08-11 | 1996-02-14 | Cellena (Cell Engineering) A.G. | Compositions de transferrine pour l'atténuation des effets secondaires des médicaments cytotoxiques |
US8771694B2 (en) * | 1994-08-12 | 2014-07-08 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for B-cell lymphoma and leukemia cells |
US5707621A (en) * | 1994-08-31 | 1998-01-13 | Chugai Pharmaceutical Co., Ltd. | Supression of nephritis-induced protein excretion by anti-IL-8 |
US6309636B1 (en) * | 1995-09-14 | 2001-10-30 | Cancer Research Institute Of Contra Costa | Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides |
US5683892A (en) * | 1994-12-23 | 1997-11-04 | Smithkline Beecham Corporation | DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
WO1996040249A1 (fr) * | 1995-06-07 | 1996-12-19 | Sloan-Kettering Institute For Cancer Research | Usages therapeutiques du ta99 |
US6001358A (en) * | 1995-11-07 | 1999-12-14 | Idec Pharmaceuticals Corporation | Humanized antibodies to human gp39, compositions containing thereof |
US6440418B1 (en) | 1995-11-07 | 2002-08-27 | Idec Pharmaceuticals Corporation | Methods of treating autoimmune diseases with gp39-specific antibodies |
GB9600660D0 (en) | 1996-01-12 | 1996-03-13 | Ciba Geigy Ag | Protein |
US6046310A (en) * | 1996-03-13 | 2000-04-04 | Protein Design Labs., Inc. | FAS ligand fusion proteins and their uses |
US5882644A (en) * | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
US6713305B1 (en) | 1996-04-29 | 2004-03-30 | Novartis Ag | Metastasis-associated antigen and antibodies thereto |
WO1997046589A2 (fr) | 1996-06-07 | 1997-12-11 | Neorx Corporation | Anticorps humanises se liant au meme antigene que celui lie par l'anticorps nr-lu-13 et leur utilisation dans des procedes de preciblage |
US6833255B1 (en) | 1996-07-24 | 2004-12-21 | Novartis, Ag | Drosophila melanogaster p70 S6 kinase |
US6534311B2 (en) | 1996-07-24 | 2003-03-18 | Novartis Ag | Drosophila melanogaster p70S6 kinase |
US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
CA2264968A1 (fr) * | 1996-09-02 | 1998-03-12 | Sumitomo Electric Industries, Ltd. | Immunoglobuline humanisee reagissant specifiquement avec un ligand fas ou l'un de ses fragments actifs et region d'induction d'apoptose prenant naissance dans un ligand fas |
US6013256A (en) * | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
CZ106299A3 (cs) | 1996-09-26 | 1999-08-11 | Chugai Seiyaku Kabushiki Kaisha | Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem |
UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
US7883872B2 (en) | 1996-10-10 | 2011-02-08 | Dyadic International (Usa), Inc. | Construction of highly efficient cellulase compositions for enzymatic hydrolysis of cellulose |
US20020160005A1 (en) | 1996-11-15 | 2002-10-31 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic urmec syndrome |
US7910096B2 (en) | 1996-11-15 | 2011-03-22 | Trustees Of Tufts College | Human neutralizing antibodies against hemolytic uremic syndrome |
DE69738841D1 (de) | 1996-12-23 | 2008-08-28 | Immunex Corp | Ligand für rezeptor aktivator of nf-kappa b, ligand ist mitglied der tnf superfamilie |
US6262238B1 (en) * | 1997-01-14 | 2001-07-17 | Roche Diagnostic, Gmbh | Process for modifying the stability of antibodies |
US6590079B2 (en) | 1997-01-30 | 2003-07-08 | Ixsys, Incorporated | Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same |
US6596850B1 (en) | 1998-01-30 | 2003-07-22 | Ixsys, Incorporated | Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same |
US20030109680A1 (en) | 2001-11-21 | 2003-06-12 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
US7749498B2 (en) | 1997-03-10 | 2010-07-06 | Genentech, Inc. | Antibodies for inhibiting blood coagulation and methods of use thereof |
US20060235209A9 (en) | 1997-03-10 | 2006-10-19 | Jin-An Jiao | Use of anti-tissue factor antibodies for treating thromboses |
US5986065A (en) | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
IL123756A0 (en) * | 1997-03-21 | 1998-10-30 | Sankyo Co | Humanized anti-human FAS antibody |
US6972323B1 (en) | 1997-04-01 | 2005-12-06 | Sankyo Company, Limited | Anti-Fas antibodies |
US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
AU743758B2 (en) | 1997-04-07 | 2002-02-07 | Genentech Inc. | Anti-VEGF antibodies |
US7365166B2 (en) | 1997-04-07 | 2008-04-29 | Genentech, Inc. | Anti-VEGF antibodies |
US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
TR199902800T2 (xx) | 1997-05-15 | 2000-04-21 | Chugai Seiyaku Kabushiki Kaisha | Ka�eksiyi tedavi edici madde. |
CA2290485C (fr) * | 1997-05-21 | 2008-08-05 | Biovation Limited | Procede de production de proteines non immunogenes |
JP4891477B2 (ja) | 1997-10-02 | 2012-03-07 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | 血管新生及び/または既存細動脈網から側枝動脈及び/または他の動脈の発達の調節に関する方法 |
EP1020522B1 (fr) * | 1997-10-03 | 2007-09-19 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain naturel |
US7964192B1 (en) | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
EP1745799B1 (fr) | 1998-03-04 | 2015-09-02 | The Trustees of The University of Pennsylvania | Compositions et méthodes pour le traitement de tumeurs |
CA2325346A1 (fr) | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humanise contre le facteur tissulaire humain (tf) et procede de production d'anticorps humanises |
HU228180B1 (hu) | 1998-08-11 | 2013-01-28 | Biogen Idec Inc | Anti-CD20-ellenanyag alkalmazása B-sejtes limfómák kombinációs terápiájára |
JP4689781B2 (ja) * | 1998-09-03 | 2011-05-25 | 独立行政法人科学技術振興機構 | アミノ酸輸送蛋白及びその遺伝子 |
SI1113810T1 (sl) | 1998-09-14 | 2009-04-30 | Univ Texas | Postopki za zdravljenje multiplega mieloma in kostne resorpcije, inducirane z mielomom, z uporabo antagonistov integrin/receptorske vezave |
EP1117808B1 (fr) | 1998-10-06 | 2004-12-29 | Mark Aaron Emalfarb | Systeme de transformation dans le domaine des hotes fongiques filamenteux |
EP1939215A1 (fr) | 1998-10-22 | 2008-07-02 | The University of Montana | Protéines Omp85 de neisseria gonorrhoeae et neisseria meningitidis, compositions contenant ces protéines et procédés d'utilisation correspondants |
DK1616572T3 (da) | 1998-11-09 | 2010-12-06 | Biogen Idec Inc | Kimært anti-CD20-antistof, rituxan, til anvendelse i behandling af kronisk lymfatisk leukæmi |
GB9825632D0 (en) | 1998-11-23 | 1999-01-13 | Novartis Ag | Organic compounds |
US20030035798A1 (en) | 2000-08-16 | 2003-02-20 | Fang Fang | Humanized antibodies |
JP2002538167A (ja) | 1999-03-03 | 2002-11-12 | バイオジェン インコーポレイテッド | 脂質の代謝および貯蔵を調節する方法 |
GB9906380D0 (en) * | 1999-03-19 | 1999-05-12 | Melvin William T | Monoclonal antibodies specific for cypibi |
EA006681B1 (ru) | 1999-04-22 | 2006-02-24 | Байоджен Айдек Ма Инк. | Применение антагонистов взаимодействия vla-4 и альфа-4-бета-7 с соответствующими альфа-4-лигандами для лечения фиброза |
IT1306704B1 (it) | 1999-05-26 | 2001-10-02 | Sirs Societa Italiana Per La R | Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf. |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
WO2000072881A1 (fr) | 1999-06-01 | 2000-12-07 | Biogen, Inc. | Anticorps monoclonal bloqueur contre vla-1 et utilisation dudit anticorps pour le traitement de troubles inflammatoires |
US7144991B2 (en) | 1999-06-07 | 2006-12-05 | Aletheon Pharmaceuticals, Inc. | Streptavidin expressed gene fusions and methods of use thereof |
US6531580B1 (en) | 1999-06-24 | 2003-03-11 | Ixsys, Inc. | Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same |
TWI255718B (en) | 1999-07-02 | 2006-06-01 | Chugai Pharmaceutical Co Ltd | Ameliorative agent for low vasopressin concentration |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
ATE388167T1 (de) * | 1999-09-30 | 2008-03-15 | Kyowa Hakko Kogyo Kk | Menschlicher antikörper gegen gangliosid gd3 für die transplantationskomplementarität bestimmente regionund derivate des antikörpers gegen das gangliosid gd3 |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
WO2001039722A2 (fr) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | Nouvelle molecule immunoregulatrice b7-h1, |
DK1242118T3 (da) | 1999-12-16 | 2010-01-11 | Biogen Idec Inc | Fremgangsmåder til behandling af iskæmisk eller hæmorrhagisk beskadigelse af centralnervesystemet under anvendelse af anti-alfa4-integrin-antagonister |
ATE474854T1 (de) | 2000-01-27 | 2010-08-15 | Medimmune Llc | Rsv neutralisierende antikörper mit sehr hohen affinität |
AU2001240020B9 (en) | 2000-03-01 | 2008-12-04 | Medimmune, Llc | High potency recombinant antibodies and method for producing them |
AU2001233277B2 (en) * | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
AU3495301A (en) | 2000-02-11 | 2001-08-20 | Biogen Inc | Heterologous polypeptide of the tnf family |
IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
WO2001070266A2 (fr) | 2000-03-17 | 2001-09-27 | Millennium Pharmaceuticals, Inc. | Methode d'inhibition de la stenose et de la restenose |
US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
ATE420661T1 (de) | 2000-04-28 | 2009-01-15 | Chugai Pharmaceutical Co Ltd | Zellproliferation-inhibitoren |
US7030219B2 (en) | 2000-04-28 | 2006-04-18 | Johns Hopkins University | B7-DC, Dendritic cell co-stimulatory molecules |
ATE412185T1 (de) | 2000-04-29 | 2008-11-15 | Univ Iowa Res Found | Diagnostika und therapeutika für makula degeneration erkrankungen |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
US7476383B2 (en) | 2000-05-02 | 2009-01-13 | The Uab Research Foundation | Antibody selective for DR4 and uses thereof |
GB0013810D0 (en) | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
GB0020685D0 (en) | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
WO2002028480A2 (fr) | 2000-10-02 | 2002-04-11 | Chiron Corporation | Methodes therapeutiques pour lutter contre les cellules b malignes |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6989247B2 (en) | 2000-11-28 | 2006-01-24 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
HUP0400986A3 (en) * | 2001-04-06 | 2012-09-28 | Univ Bristol | Use of cd25 binding molecules in steroid-resistant patients |
US7358054B2 (en) | 2001-04-13 | 2008-04-15 | Biogen Idec Ma Inc. | Antibodies to VLA-1 |
WO2002094879A1 (fr) * | 2001-05-18 | 2002-11-28 | Boehringer Ingelheim International Gmbh | Anticorps specifiques contre cd44v6 |
US6972324B2 (en) | 2001-05-18 | 2005-12-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Antibodies specific for CD44v6 |
US7541443B2 (en) * | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
AU2002314495A1 (en) | 2001-06-20 | 2003-01-02 | Prochon Biotech Ltd. | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
US20030013081A1 (en) | 2001-06-26 | 2003-01-16 | Olson William C. | Uses of DC-SIGN and DC-SIGNR for inhibiting hepatitis C virus infection |
JP4675512B2 (ja) * | 2001-07-10 | 2011-04-27 | 三井化学株式会社 | 熱殺菌方法 |
EP1578917A4 (fr) | 2001-07-19 | 2008-01-23 | Perlan Therapeutics Inc | Proteines multimeres et methodes de production et d'utilisation de ces proteines |
WO2003014162A1 (fr) * | 2001-08-03 | 2003-02-20 | Medical & Biological Laboratories Co., Ltd. | Anticorps reconnaissant la proteine beta-amyloide liee au ganglioside gm1, et adn codant l'anticorps |
AU2002329775C1 (en) | 2001-08-17 | 2011-04-07 | Eli Lilly And Company | Assay method for alzheimer's disease |
EP3467117B1 (fr) | 2001-09-20 | 2020-07-15 | Immunex Corporation | Sélection de cellules exprimant des polypeptides hétéromères |
US7241873B2 (en) | 2001-09-25 | 2007-07-10 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Recombinant anti-osteopontin antibody and use thereof |
GB0124317D0 (en) | 2001-10-10 | 2001-11-28 | Celltech R&D Ltd | Biological products |
US20030190705A1 (en) * | 2001-10-29 | 2003-10-09 | Sunol Molecular Corporation | Method of humanizing immune system molecules |
CN1585778A (zh) * | 2001-11-12 | 2005-02-23 | 默克专利有限公司 | 修饰的抗-TNFα抗体 |
EP1944043A1 (fr) | 2001-11-21 | 2008-07-16 | The Trustees of the University of Pennsylvania | Séquences d'acides aminés et d'acides nucléiques d'adénovirus simien, vecteurs les contenant, et procédés d'utilisation. |
BR0214350A (pt) | 2001-11-21 | 2005-05-10 | Univ Pennsylvania | Sequências de ácido nucleico e aminoácido de adenovìrus de sìmio, vetores contendo as mesmas e métodos de uso |
WO2003048083A2 (fr) | 2001-11-30 | 2003-06-12 | Biogen Idec Ma Inc. | Anticorps contre des proteines chimiotactiques de monocytes |
US7393648B2 (en) | 2001-12-03 | 2008-07-01 | Alexion Pharmaceuticals, Inc. | Hybrid antibodies |
WO2003048321A2 (fr) * | 2001-12-03 | 2003-06-12 | Alexion Pharmaceuticals, Inc. | Anticorps hybrides |
GB0129105D0 (en) | 2001-12-05 | 2002-01-23 | Celltech R&D Ltd | Expression control using variable intergenic sequences |
CA2476166C (fr) * | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation |
JP2006508631A (ja) * | 2002-02-22 | 2006-03-16 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | 抗ccr5抗体 |
AR038605A1 (es) | 2002-02-25 | 2005-01-19 | Elan Pharm Inc | Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento |
MY139983A (en) | 2002-03-12 | 2009-11-30 | Janssen Alzheimer Immunotherap | Humanized antibodies that recognize beta amyloid peptide |
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
WO2003080674A1 (fr) | 2002-03-20 | 2003-10-02 | Pharmacia Corporation | Isomeres de disulfure d'anticorps, utilisation de ces isomeres et procedes d'analyse de ces isomeres |
CA2480059C (fr) * | 2002-03-22 | 2015-11-24 | Amrad Operations Pty. Ltd. | Anticorps monoclonal contre le recepteur alpha1 de l'interleukine 13 (il-13ra1) |
GB0210121D0 (en) | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
ATE473284T1 (de) | 2002-05-14 | 2010-07-15 | Martek Biosciences Corp | Carotinsynthase-gen und dessen verwendung |
JP4418745B2 (ja) | 2002-05-28 | 2010-02-24 | ユセベ ファルマ ソシエテ アノニム | 抗体peg位置異性体、それを含む組成物及びその使用 |
ATE483472T1 (de) * | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
WO2003106485A1 (fr) | 2002-06-14 | 2003-12-24 | Monier Tadros | Procede de production de protamine |
GB0213745D0 (en) | 2002-06-14 | 2002-07-24 | Univ Edinburgh | Enzyme |
JP2005535636A (ja) * | 2002-06-28 | 2005-11-24 | アメリカ合衆国 | インターフェロンβおよびIL−2Rアンタゴニストを用いて自己免疫疾患を治療する方法 |
WO2010011999A2 (fr) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Procédés et compositions pour susciter une réponse immunitaire sélective envers les amyloïdes |
US7432351B1 (en) | 2002-10-04 | 2008-10-07 | Mayo Foundation For Medical Education And Research | B7-H1 variants |
GB0228832D0 (en) | 2002-12-10 | 2003-01-15 | Novartis Ag | Organic compound |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
KR20050086628A (ko) | 2002-11-15 | 2005-08-30 | 젠맵 에이/에스 | Cd25에 대한 인간 모노클로날 항체 |
EP1660535A2 (fr) | 2002-11-27 | 2006-05-31 | Minerva Biotechnologies Corporation | Techniques et compositions pour le diagnostic et le traitement du cancer (muc1) |
SI1572744T1 (sl) | 2002-12-16 | 2010-09-30 | Genentech Inc | Imunoglobulinske variante in njihove uporabe |
CA2513113A1 (fr) | 2003-01-23 | 2004-08-05 | Genentech, Inc. | Procedes de production d'anticoprs humanises et d'amelioration du rendement d'anticorps ou de fragments de liaison d'antigenes en culture cellulaire |
EP3527228A1 (fr) | 2003-01-24 | 2019-08-21 | Biogen MA Inc. | Composition permettant de traiter des maladies dues à la démyélinisation et à la paralysie par administration d'agents de remyélinisation |
EP1460088A1 (fr) | 2003-03-21 | 2004-09-22 | Biotest AG | Anticorps humanisé contre CD4 avec des caractéristiques immunosuppressives |
US7321065B2 (en) | 2003-04-18 | 2008-01-22 | The Regents Of The University Of California | Thyronamine derivatives and analogs and methods of use thereof |
US7939076B2 (en) | 2003-04-23 | 2011-05-10 | Medarex, Inc. | Methods for the therapy of Inflammatory Bowel Disease using a type-1 interferon antagonist |
ES2368737T3 (es) * | 2003-04-23 | 2011-11-21 | Medarex, Inc. | Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1). |
EP1633189B1 (fr) | 2003-05-19 | 2017-07-05 | Prothena Biosciences Limited | Fragments tronques d'alpha-synucleine dans les affections des corps de lewy |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
NZ544486A (en) | 2003-06-13 | 2009-04-30 | Biogen Idec Inc | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof |
US8153410B2 (en) | 2003-07-07 | 2012-04-10 | Fox Chase Cancer Center | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules |
US20060162014A1 (en) | 2003-07-07 | 2006-07-20 | Jaffe Eileen K | Alternate morpheeins of allosteric proteins as a target for the development of bioactive molecules |
ES2751414T5 (es) | 2003-07-08 | 2024-04-23 | Novartis Pharma Ag | Anticuerpos antagonistas a polipéptidos heterólogos IL-17 A/F |
CN103880955A (zh) | 2003-07-18 | 2014-06-25 | 安姆根有限公司 | 肝细胞生长因子的特异性结合物 |
US7834155B2 (en) | 2003-07-21 | 2010-11-16 | Immunogen Inc. | CA6 antigen-specific cytotoxic conjugate and methods of using the same |
US20060228350A1 (en) * | 2003-08-18 | 2006-10-12 | Medimmune, Inc. | Framework-shuffling of antibodies |
GB0321997D0 (en) | 2003-09-19 | 2003-10-22 | Novartis Ag | Organic compound |
WO2005044857A1 (fr) * | 2003-11-11 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Anticorps anti-cd47 humanise |
EP1687325A4 (fr) | 2003-11-12 | 2008-11-12 | Progenics Pharm Inc | Nouvelles sequences de codage de glycoproteines du virus de l'hepatite c |
US7700737B2 (en) | 2003-12-05 | 2010-04-20 | Multimmune Gmbh | Therapeutic and diagnostic anti-Hsp70 antibodies |
WO2005056599A2 (fr) | 2003-12-08 | 2005-06-23 | Morphotek, Inc. | Anticorps liant specifiquement pms2 |
AU2004299053B2 (en) | 2003-12-15 | 2011-01-06 | Alexion Pharmaceuticals, Inc. | Novel anti-DC-SIGN antibodies |
ITRM20030601A1 (it) * | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
KR101352853B1 (ko) | 2004-01-07 | 2014-02-04 | 조마 테크놀로지 리미티드 | M-csf-특이적 단일클론 항체 및 그것의 사용 |
JPWO2005068504A1 (ja) | 2004-01-19 | 2008-01-10 | 株式会社医学生物学研究所 | 炎症性サイトカイン抑制剤 |
AU2005216013B2 (en) | 2004-01-30 | 2010-11-11 | Dana Farber Cancer Institute | Method for determination and quantification of radiation or genotoxin exposure |
CA2561531C (fr) | 2004-02-10 | 2017-05-02 | The Regents Of The University Of Colorado | Inhibition du facteur b et de la voie du complement alternative et procedes associes |
CA2556027C (fr) | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Anticorps monoclonaux qui bloquent specifiquement l'activite biologique d'un antigene tumoral |
TWI359026B (en) | 2004-02-12 | 2012-03-01 | Sankyo Co | Pharmaceutical composition for the osteoclast rela |
EP1717250A4 (fr) | 2004-02-20 | 2008-10-01 | Immuno Biological Lab Co Ltd | Anticorps monoclonal et utilisation de celui-ci |
EP2287194B1 (fr) | 2004-03-12 | 2016-10-26 | Vasgene Therapeutics, Inc. | Anticorps anti-EphB4 pour inhiber l'angiogénèse et la croissance tumorale |
US7625549B2 (en) | 2004-03-19 | 2009-12-01 | Amgen Fremont Inc. | Determining the risk of human anti-human antibodies in transgenic mice |
CA2564989C (fr) | 2004-03-19 | 2014-05-27 | Amgen, Inc. | Reduction du risque d'anticorps humains et anti-humains par la manipulation du gene v |
MY162179A (en) | 2004-04-01 | 2017-05-31 | Elan Pharm Inc | Steroid sparing agents and methods of using same |
EP2394662B1 (fr) | 2004-04-02 | 2018-03-21 | The Regents of The University of California | Compositions et méthodes de traitement et de prevention d'une maladie associée a l'integrine alpha v beta 5 |
US8492106B2 (en) | 2004-05-24 | 2013-07-23 | Universitat Zu Koln | Identification methods for ergothioneine transporter modulators and therapeutic uses thereof |
EP1602926A1 (fr) | 2004-06-04 | 2005-12-07 | University of Geneva | Nouveaux moyens et méthodes pour le traitement de pertes d'audition ou l'audition fantôme |
PT2662390T (pt) | 2004-06-21 | 2017-10-09 | Squibb & Sons Llc | Anticorpos contra recetor 1 do interferão alfa e as suas utilizações |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
EP1791563A4 (fr) | 2004-07-26 | 2009-07-08 | Biogen Idec Inc | Anticorps anti-cd154 |
GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
MX2007001679A (es) | 2004-08-09 | 2007-05-23 | Elan Pharm Inc | Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica. |
CA2478458A1 (fr) | 2004-08-20 | 2006-02-20 | Michael Panzara | Traitement de la sclerose en plaques pediatrique |
FI20041204A0 (fi) | 2004-09-16 | 2004-09-16 | Riikka Lund | Menetelmät immuunivälitteisiin sairauksiin liittyvien uusien kohdegeenien hyödyntämiseksi |
ATE497508T1 (de) | 2004-10-01 | 2011-02-15 | Max Planck Gesellschaft | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper |
US7892540B2 (en) | 2004-10-06 | 2011-02-22 | Mayo Foundation For Medical Education And Research | B7-H1 and methods of diagnosis, prognosis, and treatment of cancer |
JP5553963B2 (ja) | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
AU2005306997B2 (en) | 2004-10-25 | 2012-07-05 | Merck Sharp & Dohme Corp. | Anti-ADDL antibodies and uses thereof |
CN103169965A (zh) | 2004-11-19 | 2013-06-26 | 比奥根艾迪克Ma公司 | 治疗多发性硬化 |
PE20061329A1 (es) | 2004-12-15 | 2006-12-08 | Neuralab Ltd | Anticuerpos ab humanizados para mejorar la cognicion |
PT2028193E (pt) | 2005-01-05 | 2012-06-15 | Star Biotech Forschung Entw Gmbh | Domínios de imunoglobulina sintéticos com propriedades de ligação modificadas em regiões da molécula diferentes das regiões de determinação de complementaridade |
PT2682126T (pt) | 2005-01-27 | 2017-02-28 | Children`S Hospital & Res Center At Oakland | Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis |
US8088579B2 (en) | 2005-02-14 | 2012-01-03 | University Of Iowa Research Foundation | Complement factor H for diagnosis of age-related macular degeneration |
AU2006214179A1 (en) | 2005-02-17 | 2006-08-24 | Biogen Idec Ma Inc. | Treating neurological disorders |
AU2006216291B2 (en) | 2005-02-27 | 2011-01-27 | Institute For Antibodies Co., Ltd. | Anti-IgSF4 antibody and utilization of the same |
JP2008531719A (ja) | 2005-03-02 | 2008-08-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Th2介在性状態の治療のためのKIM−1抗体 |
WO2006099141A2 (fr) | 2005-03-10 | 2006-09-21 | Morphotek, Inc. | Anticorps diriges contre la mesotheline |
JP2008532559A (ja) | 2005-03-19 | 2008-08-21 | メディカル リサーチ カウンシル | ウイルス感染の治療及び予防又は治療及び予防の改善 |
WO2006105021A2 (fr) | 2005-03-25 | 2006-10-05 | Tolerrx, Inc. | Molecules de liaison gitr et leurs utilisations |
EP2526957A3 (fr) | 2005-03-30 | 2013-02-20 | Minerva Biotechnologies Corporation | Prolifération des cellules exprimant MUC1 |
DK1875244T3 (en) | 2005-03-30 | 2019-04-29 | Minerva Biotechnologies Corp | Proliferation of MUC1-Expressing Cells |
KR20140068234A (ko) | 2005-03-31 | 2014-06-05 | 더 제너럴 하스피탈 코포레이션 | Hgf/hgfr 활성의 모니터링 및 조정 |
PL2645106T3 (pl) | 2005-04-04 | 2017-11-30 | Biogen Ma Inc. | Sposoby oceniania odpowiedzi immunologicznej na środek leczniczy |
CA2607455A1 (fr) | 2005-04-22 | 2006-11-02 | Morphotek, Inc. | Anticorps a activite d'effecteur immunitaire et internalises dans des cellules positives vis-a-vis de l'endosialine |
JP2009521206A (ja) | 2005-04-22 | 2009-06-04 | モルフォテック、インク. | 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体 |
US20090041783A1 (en) | 2005-04-28 | 2009-02-12 | Mochida Pharmaceutical Co., Ltd. | Anti-platelet membrane glycoprotein vi monoclonal antibody |
EP1885396A2 (fr) | 2005-05-04 | 2008-02-13 | Quark Pharmaceuticals, Inc. | Anticorps recombinants diriges contre cd55 et cd59 et leur utilisation |
KR101562549B1 (ko) | 2005-05-10 | 2015-10-23 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나제의 조절제 및 이의 사용방법 |
AU2006247188A1 (en) | 2005-05-18 | 2006-11-23 | Children's Hospital & Research Center At Oakland | Methods and compositions for immunizing against chlamydia infection |
AU2006247039B2 (en) | 2005-05-19 | 2011-03-03 | Amgen Inc. | Compositions and methods for increasing the stability of antibodies |
AU2006249835B2 (en) | 2005-05-26 | 2011-09-08 | Musc Foundation For Research Development | Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions |
UA96416C2 (uk) | 2005-05-27 | 2011-11-10 | Байоджэн Айдэк Ма Инк. | Антитіло, яке зв'язується з tweak людини |
EP2364998A1 (fr) | 2005-06-16 | 2011-09-14 | The Feinstein Institute for Medical Research | Anticorps contre le HMGB1 et fragments associés |
WO2006138739A2 (fr) | 2005-06-17 | 2006-12-28 | Tolerx, Inc. | Molecules de liaison ilt3 et leurs utilisations |
ES2569917T3 (es) * | 2005-06-21 | 2016-05-13 | Xoma (Us) Llc | Anticuerpos y fragmentos de los mismos que se unen a IL-1beta |
CN102875681A (zh) | 2005-07-08 | 2013-01-16 | 拜奥根Idec马萨诸塞公司 | 抗-αvβ6抗体及其用途 |
FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
AU2006272750B2 (en) | 2005-07-22 | 2011-09-29 | Cytodyn, Inc. | Methods for reducing viral load in HIV-1-infected patients |
WO2007016285A2 (fr) | 2005-07-28 | 2007-02-08 | Novartis Ag | Anticorps monoclonal specifique de m-csf et ses utilisations |
US8193328B2 (en) | 2005-09-08 | 2012-06-05 | Philadelphia Health & Education Corporation | Identification of modulators of serine protease inhibitor Kazal and their use as anti-cancer and anti-viral agents |
CN101313216A (zh) | 2005-09-22 | 2008-11-26 | 普洛茨股份有限公司 | 酵母突变体中产生的糖基化多肽及其使用方法 |
EP1946768A4 (fr) | 2005-10-28 | 2009-11-11 | Meiji Seika Kaisha | Proteine de couche exterieure pa5158 de pseudomonas aeruginosa |
WO2007051077A2 (fr) | 2005-10-28 | 2007-05-03 | The Regents Of The University Of California | Methodes et composes de detection et d'isolement de cellules lymphomatiques |
RS53055B (en) | 2005-11-01 | 2014-04-30 | Abbvie Biotechnology Ltd | PROCEDURES FOR DETERMINING THE EFFICIENCY OF ADALIMUMAB IN RESPONDENTS WHO HAVE ANKILLOSATIVE SPONDILITIS USING CTX-II AND MMP3 AS BIOMARKERS |
CA2627446A1 (fr) | 2005-11-21 | 2007-05-31 | Laboratoires Serono S.A. | Compositions et methodes de production de molecules hybrides de fixant a des antigenes, et leurs utilisations |
PL1976877T5 (pl) | 2005-11-30 | 2017-09-29 | Abbvie Inc | Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania |
DOP2006000277A (es) | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | Anticuerpos anti mn y métodos para su utilización |
EP2272497B1 (fr) | 2006-01-18 | 2012-10-03 | The General Hospital Corporation | Procédés pour augmenter la fonction lymphatique |
JP2009531295A (ja) | 2006-02-22 | 2009-09-03 | ユニバーシティ オブ チューリッヒ | 自己免疫疾患又は脱髄疾患を処置するための方法 |
EP1996622A2 (fr) | 2006-03-10 | 2008-12-03 | Zymogenetics, Inc. | Anticorps se liant à la fois avec il-17a et il-17f et procédés d'utilisation |
US9315578B2 (en) | 2006-03-23 | 2016-04-19 | Tohoku Univeristy | High functional bispecific antibody |
SG170804A1 (en) | 2006-03-30 | 2011-05-30 | Meiji Seika Kaisha | Pseudomonas aeruginosa outer membrane protein pa0427 |
EP2004689A4 (fr) | 2006-04-05 | 2010-06-02 | Abbott Biotech Ltd | Purification d'anticorps |
CA2564435A1 (fr) | 2006-04-10 | 2007-10-10 | Abbott Biotechnology Ltd. | Methodes de controle et de traitement des troubles intestinaux |
EP2666472A3 (fr) | 2006-04-10 | 2014-04-02 | Abbott Biotechnology Ltd | Utilisations et compositions pour le traitement de l'arthrite psoriasique |
EP2666478A3 (fr) | 2006-04-10 | 2014-10-22 | AbbVie Biotechnology Ltd | Utilisations et compositions pour le traitement du psoriasis |
CN105381459A (zh) | 2006-05-25 | 2016-03-09 | 比奥根Ma公司 | 治疗中风的方法 |
RU2429016C2 (ru) | 2006-05-31 | 2011-09-20 | Астеллас Фарма Инк. | Гуманизированное антитело против остеопонтина человека |
JP2009538924A (ja) | 2006-06-01 | 2009-11-12 | エラン ファーマシューティカルズ,インコーポレイテッド | Appの神経活性断片 |
WO2007144893A2 (fr) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Anticorps bloquant l'activation du récepteur du facteur de croissance des fibroblastes et leurs procédés d'utilisation |
AU2007345745C1 (en) | 2006-06-19 | 2013-05-23 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
KR101396797B1 (ko) | 2006-06-30 | 2014-05-26 | 애브비 바이오테크놀로지 리미티드 | 자동 주사 장치 |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
EP2059531A1 (fr) | 2006-07-07 | 2009-05-20 | Intercell AG | Petits antigènes de streptococcus pyogenes et leur utilisation |
EP2078732B1 (fr) | 2006-07-10 | 2015-09-16 | Fujita Health University | Procédé pour l'identification des anticorps diagnostic ou thérapeutiques par cytométrie en flux |
EP2046374A4 (fr) | 2006-07-10 | 2010-05-05 | Biogen Idec Inc | COMPOSITIONS ET MÉTHODES VISANT À INHIBER LA CROISSANCE DE CANCERS À DÉFICIENCE EN smad4 |
ES2452067T3 (es) | 2006-08-04 | 2014-03-31 | Novartis Ag | Anticuerpo específico para EPHB3 y usos del mismo |
US9415111B2 (en) | 2006-08-11 | 2016-08-16 | Rutgers, The State University Of New Jersey | Dual-sensitizer-containing luminescent compounds, conjugates, and uses thereof |
EA201201533A1 (ru) | 2006-08-18 | 2014-11-28 | Новартис Аг | Prlr-специфическое антитело и его применения |
EP2500416A1 (fr) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Améliorations de culture cellulaire |
WO2008033517A2 (fr) | 2006-09-13 | 2008-03-20 | Abbott Laboratories | Améliorations à la culture de cellules |
US20100297103A1 (en) | 2006-09-14 | 2010-11-25 | Medical & Biological Laboratories Co., Ltd. | Antibody having enhanced adcc activity and method for production thereof |
FR2906533B1 (fr) | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
WO2008052796A1 (fr) | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Anticorps anti-fgfr4 |
CN103073641B (zh) | 2006-11-10 | 2015-01-21 | 株式会社立富泰克 | 在体内具有抗肿瘤活性的抗人Dlk-1抗体 |
AU2007321817A1 (en) | 2006-11-17 | 2008-05-22 | Novartis Ag | Lingo binding molecules and pharmaceutical use thereof |
EP1923069A1 (fr) | 2006-11-20 | 2008-05-21 | Intercell AG | Peptides protecteurs contre S. pneumoniae et compositions, méthodes et utilisations associés |
US8288110B2 (en) | 2006-12-04 | 2012-10-16 | Perkinelmer Health Sciences, Inc. | Biomarkers for detecting cancer |
CA2672120A1 (fr) | 2006-12-07 | 2008-06-12 | Novartis Ag | Anticorps antagonistes contre ephb3 |
EP2102366A4 (fr) | 2006-12-10 | 2010-01-27 | Dyadic International Inc | Expression et criblage a haut debit de bibliotheques d'adn exprime complexes dans les champignons filamenteux |
WO2008083169A2 (fr) | 2006-12-26 | 2008-07-10 | The Johns Hopkins University | Compositions et procédés pour le traitement de troubles immunologiques |
AU2007339762B2 (en) | 2006-12-27 | 2011-03-31 | The Johns Hopkins University | Compositions and methods for treating inflammation and auto-immune diseases |
US7989173B2 (en) | 2006-12-27 | 2011-08-02 | The Johns Hopkins University | Detection and diagnosis of inflammatory disorders |
WO2008083331A2 (fr) | 2006-12-29 | 2008-07-10 | The Regents Of The University Of Colorado | Diagnostic et cible thérapeutique pour des maladies autoimmunes et leurs utilisations |
CA2764852C (fr) | 2007-01-05 | 2018-09-18 | University Of Zurich | Procede pour fournir des molecules de liaison et des cibles specifiques a une maladie. |
WO2008084072A2 (fr) | 2007-01-12 | 2008-07-17 | Intercell Ag | Protéines protectrices de s. agalactia, leurs combinaisons et leurs procédés d'utilisation |
US8168415B2 (en) | 2007-02-07 | 2012-05-01 | The Regents Of The University Of Colorado | Axl fusion proteins as Axl tyrosine kinase inhibitors |
SI2130044T1 (sl) | 2007-02-16 | 2017-03-31 | Genzyme Corporation | Postopek prepoznavanja tveganja motnje ščitnice |
PT3067066T (pt) | 2007-02-23 | 2019-06-17 | Univ California | Prevenção e tratamento da doença sinucleinopática e amiloidogénica |
CN101663047B (zh) | 2007-02-23 | 2014-07-09 | 纽约哥伦比亚大学理事会 | 通过激活或阻断HLA-E/Qa-1限制性CD8+T细胞调控途径来治疗免疫疾病的方法 |
PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
PT2457928T (pt) | 2007-03-13 | 2017-08-17 | Univ Zuerich | Anticorpo monoclonal humano específico de tumores |
CA2681530C (fr) | 2007-03-22 | 2017-03-28 | Biogen Idec Ma Inc. | Proteines liantes, y compris des anticorps, derives d'anticorps et fragments d'anticorps qui lient specifiquement cd154 |
BRPI0809665B8 (pt) | 2007-04-05 | 2021-05-25 | Eisai Inc | anticorpo monoclonal que se liga especificamente a endosialina |
WO2008134659A2 (fr) | 2007-04-27 | 2008-11-06 | Zymogenetics, Inc. | Antagonistes à il-17a, il-17f et il-23p19, et procédés d'utilisation de ceux-ci |
EP2360177A1 (fr) | 2007-05-02 | 2011-08-24 | Intercell AG | Antigènes de Klebsiella |
WO2008143797A1 (fr) | 2007-05-11 | 2008-11-27 | Genzyme Corporation | Procédés de production de protéine sécrétée |
EP1997830A1 (fr) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | Molécules à liaison spécifiques RSV et leur moyen de fabrication |
US7709215B2 (en) | 2007-06-01 | 2010-05-04 | Cytonics Corporation | Method for diagnosing and treating acute joint injury |
US8999337B2 (en) | 2007-06-11 | 2015-04-07 | Abbvie Biotechnology Ltd. | Methods for treating juvenile idiopathic arthritis by inhibition of TNFα |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
TWI614028B (zh) | 2007-06-14 | 2018-02-11 | 百健Ma公司 | 抗體調配物 |
AU2008265218A1 (en) | 2007-06-18 | 2008-12-24 | Intercell Ag | Chlamydia antigens |
US8921279B2 (en) | 2007-06-26 | 2014-12-30 | F-Star Biotechnologische Forschungs—und Entwicklungsges. m.b.H | Display of binding agents |
WO2009001940A1 (fr) | 2007-06-27 | 2008-12-31 | Asubio Pharma Co., Ltd. | Remède anticancéreux contenant un anticorps dirigé contre un peptide codé par l'exon-17 de la périostine |
EP2014681A1 (fr) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Nouveaux anticorps à inhibition de dimérisation c-met, et utilisations correspondantes |
ES2591281T3 (es) | 2007-07-12 | 2016-11-25 | Gitr, Inc. | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
AU2008293885A1 (en) | 2007-07-13 | 2009-03-05 | The John Hopkins University | B7-DC variants |
JP5312459B2 (ja) | 2007-08-02 | 2013-10-09 | ジリード バイオロジクス,インク. | Loxおよびloxl2阻害剤ならびにこれらの使用 |
MY150621A (en) | 2007-08-30 | 2014-02-14 | Daiichi Sankyo Co Ltd | Anti-epha2 antibody |
JPWO2009031230A1 (ja) * | 2007-09-06 | 2010-12-09 | 国立大学法人大阪大学 | 抗cd20モノクローナル抗体 |
WO2009033071A2 (fr) | 2007-09-07 | 2009-03-12 | Dyadic International, Inc. | Enzymes fongiques inédites |
EP2185592B1 (fr) | 2007-09-13 | 2013-01-23 | University Of Zurich Prorektorat Forschung | Anticorps monoclonal anti-bêta-amyloide (abêta) et ses utilisations |
MX2010002683A (es) | 2007-09-14 | 2010-03-26 | Amgen Inc | Poblaciones de anticuerpos homogeneos. |
EP2586795B1 (fr) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Utilisation d'anticorps anti-beta amyloide aux maladies oculaires |
PL2206727T3 (pl) | 2007-10-11 | 2015-08-31 | Daiichi Sankyo Co Ltd | Przeciwciało skierowane na białko Siglec-15 związane z osteoklastami |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
AU2008312802A1 (en) | 2007-10-19 | 2009-04-23 | Immunas Pharma, Inc. | Antibody capable of specifically binding to abeta oligomer, and use thereof |
CA2866649A1 (fr) | 2007-11-01 | 2009-05-07 | University Of Iowa Research Foundation | Analyse de lieu de rca pour estimer la sensibilite a l'amd et au mpgnii |
AU2008317724B2 (en) | 2007-11-02 | 2011-06-02 | Novartis Ag | Improved Nogo-A binding molecules and pharmaceutical use thereof |
JP2011514881A (ja) | 2007-11-09 | 2011-05-12 | ザ ソルク インスティテュート フォー バイオロジカル スタディーズ | 免疫増強剤としてのtam受容体阻害剤の使用および免疫抑制剤としてのtam活性化剤の使用 |
AU2008323206B2 (en) | 2007-11-12 | 2014-08-14 | U3 Pharma Gmbh | AXL antibodies |
EP2463362B1 (fr) | 2007-11-28 | 2017-11-08 | The Trustees Of The University Of Pennsylvania | Adénovirus SAdv-31 de la sous-famille C des simiens et ses utilisations |
CA2706258C (fr) | 2007-11-28 | 2017-06-06 | The Trustees Of The University Of Pennsylvania | Adenovirus simiens sadv-39, -25.2, -26, -30, -37, et -38 de la sous-famille e et utilisations de ceux-ci |
WO2009079242A2 (fr) | 2007-12-05 | 2009-06-25 | Massachusetts Institute Of Technology | Mutants d'immunoglobuline aglycosylée |
US8779088B2 (en) | 2007-12-17 | 2014-07-15 | Marfl Ab | Vaccine for the treatment of Mycobacterium related disorders |
WO2009081955A1 (fr) | 2007-12-25 | 2009-07-02 | Meiji Seika Kaisha, Ltd. | Protéine composante pa1698 pour le système de sécrétion de type-iii de pseudomonas aeruginosa |
EP2730659A3 (fr) | 2007-12-28 | 2016-01-13 | Prothena Biosciences Limited | Traitement et Prophylaxie de L'amylose |
CA2711882C (fr) | 2008-01-11 | 2016-07-19 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Amelioration de l'anticorps humanise anti-integrine a9 humaine |
JP2011509650A (ja) | 2008-01-11 | 2011-03-31 | 株式会社ジーンテクノサイエンス | ヒト化抗−α9インテグリン抗体及びその使用 |
BRPI0906492A2 (pt) | 2008-01-11 | 2015-12-01 | Synovex Corp | antagonistas da caderina-11 e métodos para o tratamento de doenças inflamatórias das articulações |
CA2714413C (fr) | 2008-02-08 | 2017-01-24 | Immunas Pharma, Inc. | Anticorps capable de se fixer specifiquement a un oligomere b et utilisation dudit anticorps |
JP5661476B2 (ja) | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途 |
SG190627A1 (en) | 2008-03-13 | 2013-06-28 | Biotest Ag | Agent for treating disease |
JP5597553B2 (ja) | 2008-03-13 | 2014-10-01 | バイオテスト・アクチエンゲゼルシヤフト | 疾患治療剤 |
RU2540013C2 (ru) | 2008-03-13 | 2015-01-27 | Биотест Аг | Средство для лечения заболевания |
ES2527521T3 (es) | 2008-03-17 | 2015-01-26 | Livtech Inc. | Anticuerpos antihumanos frente a Dlk-1 que tienen actividad antitumoral |
BRPI0909664A2 (pt) | 2008-03-17 | 2019-09-24 | Intercell Ag | peptídios protetores contra s. pneumoniae e composições, métodos e usos relacionados com os mesmos |
EP2268313A2 (fr) | 2008-03-17 | 2011-01-05 | Universitätsklinikum Münster | Protéine yopm utilisée comme véhicule pour les molécules cargo et comme agent thérapeutique biologique pour l immunomodulation de réactions inflammatoires |
US20110028697A1 (en) | 2008-03-27 | 2011-02-03 | Takara Bio Inc. | Prophylactic/therapeutic agent for infectious disease |
MY159553A (en) | 2008-04-11 | 2017-01-13 | Seattle Genetics Inc | Detection and treatment of pancreatic, ovarian and other cancers |
EP2113255A1 (fr) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Immunoglobuline cytotoxique |
PL2282773T3 (pl) | 2008-05-02 | 2014-08-29 | Seattle Genetics Inc | Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej |
JP2011523560A (ja) | 2008-06-02 | 2011-08-18 | ダナ−ファーバー キャンサー インスティテュート インク. | Xbp1ペプチド、cd138ペプチドおよびcs1ペプチド |
KR20110038047A (ko) | 2008-06-20 | 2011-04-13 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 산화 LDL/β2GPI복합체에 대한 항체 및 그 용도 |
TR201808591T4 (tr) | 2008-06-25 | 2018-07-23 | Esbatech Alcon Biomed Res Unit | Bir evrensel bir antikor iskeleti kullanılarak tavşan antikorların insanlaştırılması. |
BRPI0914319B8 (pt) | 2008-06-25 | 2021-05-25 | Esbatech Alcon Biomed Res Unit | imunoligante que se liga especificamente ao tnf alfa humano e composição |
ES2890405T3 (es) | 2008-06-25 | 2022-01-19 | Novartis Ag | Humanización de anticuerpos de conejo usando un armazón de anticuerpo universal |
PE20110308A1 (es) | 2008-07-08 | 2011-06-10 | Incyte Corp | 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa |
WO2010008051A1 (fr) | 2008-07-16 | 2010-01-21 | 株式会社医学生物学研究所 | Anticorps anti-clcp1 humain et son utilisation |
US9102734B2 (en) | 2009-03-10 | 2015-08-11 | Baylor Research Institute | Fusion proteins comprising antibody and HPV E6 and E7 antigens |
WO2010013498A1 (fr) | 2008-08-01 | 2010-02-04 | 学校法人聖マリアンナ医科大学 | Agent thérapeutique ou agent préventif pour l'arthrose |
US8795981B2 (en) | 2008-08-08 | 2014-08-05 | Molecular Devices, Llc | Cell detection |
US8417011B2 (en) | 2008-09-18 | 2013-04-09 | Molecular Devices (New Milton) Ltd. | Colony detection |
EP2172485A1 (fr) | 2008-10-01 | 2010-04-07 | Pierre Fabre Medicament | Nouveaux anticorps anti CXCR4 et leur utilisation dans le traitement contre le cancer |
US8715654B2 (en) | 2008-10-02 | 2014-05-06 | Celtaxsys, Inc. | Methods of modulating the negative chemotaxis of immune cells |
JP2012505636A (ja) | 2008-10-09 | 2012-03-08 | ミネルバ バイオテクノロジーズ コーポレーション | 細胞において多能性を誘導する方法 |
DK2346904T3 (en) | 2008-10-29 | 2017-06-12 | China Synthetic Rubber Corp | METHODS AND METHODS OF DIAGNOSIS AND TREATMENT OF HEPATOCELLULAR CARCINOM |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
EP2774985B1 (fr) | 2008-10-31 | 2016-12-14 | The Trustees Of The University Of Pennsylvania | Adénovirus simien SAdV-43 et son utilisations |
AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
US9469691B2 (en) | 2008-12-02 | 2016-10-18 | Pierre Fabre Medicament | Anti-cMET antibody |
SI2370466T1 (sl) | 2008-12-19 | 2015-11-30 | Biogen International Neuroscience Gmbh | Človeška avtoprotitelesa proti alfa-sinukleinu |
US8313915B2 (en) | 2009-01-21 | 2012-11-20 | Gundersen Lutheran Medical Foundation, Inc. | Early detection of canine lyme disease by specific peptides and antibodies |
US20100260752A1 (en) | 2009-01-23 | 2010-10-14 | Biosynexus Incorporated | Opsonic and protective antibodies specific for lipoteichoic acid of gram positive bacteria |
WO2010089340A2 (fr) | 2009-02-05 | 2010-08-12 | Intercell Ag | Peptides protecteurs contre e. faecalis, procédés et utilisations liés à ceux-ci |
WO2010092176A2 (fr) | 2009-02-13 | 2010-08-19 | Intercell Ag | Antigènes haemophilus influenzae non typables |
WO2010096658A1 (fr) | 2009-02-19 | 2010-08-26 | The Cleveland Clinic Foundation | Corine en tant que marqueur pour une insuffisance cardiaque |
PT2406286T (pt) | 2009-03-10 | 2016-08-19 | Baylor Res Inst | Anticorpos anti-cd40 e seus usos |
MX2011009439A (es) | 2009-03-10 | 2013-06-18 | Baylor Res Inst | Vacunas con especificidad de objetivo hacia celula presentadora de antigeno. |
JP5725508B2 (ja) | 2009-03-25 | 2015-05-27 | 国立大学法人東北大学 | Lh型二重特異性抗体 |
JP5653909B2 (ja) | 2009-04-09 | 2015-01-14 | 第一三共株式会社 | 抗Siglec−15抗体 |
CA2758322C (fr) | 2009-04-10 | 2019-04-02 | Tufts Medical Center, Inc. | Activation de par-1 par la metalloproteinase-1 (mmp-1) |
US9090679B2 (en) | 2009-04-17 | 2015-07-28 | Immunas Pharma, Inc. | Antibodies that specifically bind to A beta oligomers and use thereof |
WO2012055980A1 (fr) | 2010-10-27 | 2012-05-03 | Pierre Fabre Medicament | Anticorps utilisés pour traiter le vih |
EP2246364A1 (fr) | 2009-04-29 | 2010-11-03 | Pierre Fabre Médicament | Anticorps anti CXCR4 pour le traitement du VIH |
WO2010127146A1 (fr) | 2009-04-29 | 2010-11-04 | Abbott Biotechnology Ltd | Dispositif d'injection automatique |
EP2270053A1 (fr) | 2009-05-11 | 2011-01-05 | U3 Pharma GmbH | Anticorps AXL humanisés |
WO2010138675A1 (fr) | 2009-05-29 | 2010-12-02 | The Trustees Of The University Of Pennsylvania | Adénovirus simien 41 et ses utilisations |
EP2260864A1 (fr) | 2009-06-10 | 2010-12-15 | University of Melbourne | Applications thérapeutiques |
TWI513465B (zh) | 2009-06-25 | 2015-12-21 | Regeneron Pharma | 以dll4拮抗劑與化學治療劑治療癌症之方法 |
JP5755647B2 (ja) | 2009-07-24 | 2015-07-29 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | αvβ5インテグリンに関連する疾患の処置および予防のための方法および組成物 |
CA2768330A1 (fr) | 2009-07-28 | 2011-02-03 | F. Hoffmann-La Roche Ag | Procede non invasif d'imagerie optique in vivo |
CA2770237A1 (fr) | 2009-08-05 | 2011-02-10 | Nexigen Gmbh | Proteines interagissant avec le hcv humain et procedes d'utilisation |
WO2011024114A1 (fr) | 2009-08-25 | 2011-03-03 | Ecole Polytechnique Federale De Lausanne (Epfl) | Molécules de matrice extracellulaire de ciblage pour le traitement du cancer |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
AU2010286361A1 (en) | 2009-08-31 | 2012-03-15 | Amplimmune, Inc. | Methods and compositions for the inhibition of transplant rejection |
EP2477647B1 (fr) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation de produits d'immunothérapie à base de levure et réponses associées |
EP2305285A1 (fr) | 2009-09-29 | 2011-04-06 | Julius-Maximilians-Universität Würzburg | Supports et procédés pour traiter les conditions ischémiques |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
EP2308897A1 (fr) | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Anticorps chimères spécifiques de CD151 et leurs utilisations pour le traitement du cancer |
JP2013507618A (ja) | 2009-10-11 | 2013-03-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 抗vla‐4関連アッセイ |
US8921525B2 (en) | 2009-11-18 | 2014-12-30 | Tohoku University | Highly-functional mutant of humanized anti-EGFR antibody variable region |
EP2332929A1 (fr) | 2009-11-25 | 2011-06-15 | ArisGen SA | Dérivés d'orthoester d'éthers couronne comme vehicules pour compositions diagnostiques et pharmaceutiques |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
WO2011068870A2 (fr) | 2009-12-01 | 2011-06-09 | President And Fellows Of Harvard College | Modulation de l'activité d'effecteur spécifique de l'antigène de cellules nk par la modulation de cxcr6 (cd186) |
JP2013514388A (ja) | 2009-12-16 | 2013-04-25 | フィリップ ボッシュ, | 間質性膀胱炎の処置の方法 |
US9221759B2 (en) | 2010-01-13 | 2015-12-29 | Rutgers, The State University Of New Jersey | Fluorophore chelated lanthanide luminescent probes with improved quantum efficiency |
CA2787755A1 (fr) | 2010-01-20 | 2011-07-28 | Tolerx, Inc. | Immunoregulation par des anticorps anti-ilt5 et fragments d'anticorps se liant a ilt5 |
US9023997B2 (en) | 2010-01-20 | 2015-05-05 | Merck Sharp & Dohme Corp. | Anti-ILT5 antibodies and ILT5-binding antibody fragments |
CN102821786B (zh) | 2010-01-29 | 2016-01-13 | 阿克西斯股份有限公司 | 含有骨关节炎治疗剂的注射液 |
RU2012132241A (ru) | 2010-01-29 | 2014-03-10 | Аксис, Инк. | Фармацевтическая композиция для лечения или профилактики остеоартрита и способ ее производства |
JP2012246222A (ja) | 2010-01-29 | 2012-12-13 | Axis Inc | 変形性関節症治療剤または予防剤を製造するための使用 |
EP2531613A2 (fr) | 2010-02-02 | 2012-12-12 | Abbott Biotechnology Ltd. | Procédés et compositions de prédiction de la réponse à un traitement avec un inhibiteur du tnf-alpha |
MX2012008884A (es) | 2010-02-08 | 2012-08-31 | Agensys Inc | Conjugados de anticuerpo y farmaco (adc) que se unen a proteinas 161p2f10b. |
RU2565539C2 (ru) | 2010-02-18 | 2015-10-20 | Те Риджентс Оф Те Юниверсити Оф Калифорния | АНТИТЕЛА, НЕЙТРАЛИЗУЮЩИЕ ИНТЕГРИН ανβ8 |
WO2011109398A2 (fr) | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Procédés et compositions pour le traitement du syndrome d'angelman et des troubles du spectre autistique |
KR101831459B1 (ko) * | 2010-03-03 | 2018-04-04 | 더 유니버시티 오브 브리티시 콜롬비아 | 올리고머 특이적 아밀로이드 베타 에피토프 및 항체 |
EP2553449A2 (fr) | 2010-03-26 | 2013-02-06 | Westfälische Wilhelms-Universität Münster | Thérapie de substitution pour glucocorticoïdes |
EP2371863A1 (fr) | 2010-03-30 | 2011-10-05 | Pierre Fabre Médicament | Anticorps humanisé anti CXCR4 pour le traitement du cancer |
CN103154027B (zh) | 2010-04-09 | 2016-06-29 | 重症监护诊断股份有限公司 | 可溶性人st-2抗体和分析法 |
PL3202789T3 (pl) | 2010-04-16 | 2020-09-21 | Biogen Ma Inc. | Przeciwciała anty-vla-4 |
ES2727275T3 (es) | 2010-04-21 | 2019-10-15 | Abbvie Biotechnology Ltd | Dispositivo automático de inyección portátil para la liberación controlada de agentes terapéuticos |
MX2012012736A (es) | 2010-05-07 | 2013-02-26 | Hoffmann La Roche | Metodo de diagnostico para la deteccion de celulas ex vivo. |
SG10201503904XA (en) | 2010-05-17 | 2015-06-29 | Livtech Inc | Anti-human trop-2 antibody having antitumor activity in vivo |
WO2011146727A1 (fr) | 2010-05-19 | 2011-11-24 | Philip Bosch | Méthodes de traitement de la cystite interstitielle |
WO2012005076A1 (fr) | 2010-07-08 | 2012-01-12 | 本田技研工業株式会社 | Bobine de chauffage haute fréquence |
WO2012009442A2 (fr) | 2010-07-14 | 2012-01-19 | Merck Sharp & Dohme Corp. | Anticorps monoclonal anti-addl et ses utilisations |
LT2593128T (lt) | 2010-07-15 | 2018-06-25 | Adheron Therapeutics, Inc. | Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai |
CN107337735B (zh) | 2010-07-29 | 2021-06-22 | 巴扎德制药公司 | 嵌合il-1受体i型激动剂和拮抗剂 |
CN103179981B (zh) | 2010-07-30 | 2017-02-08 | Ac免疫有限公司 | 安全和功能性的人源化抗β‑淀粉样蛋白抗体 |
JP2012034668A (ja) | 2010-08-12 | 2012-02-23 | Tohoku Univ | ヒト型化抗egfr抗体リジン置換可変領域断片及びその利用 |
WO2012027494A1 (fr) | 2010-08-24 | 2012-03-01 | Regents Of The University Of Minnesota | Réactifs bispécifiques de ciblage |
CA2807244A1 (fr) | 2010-08-27 | 2012-03-01 | University Of Zurich | Nouvelle cible diagnostique et therapeutique pour affections inflammatoires et/ou cardiovasculaires |
EP2609431B1 (fr) | 2010-08-27 | 2017-05-10 | University of Zurich | Procédé de validation de cibles et de médicaments pour des affections inflammatoires et/ou cardiovasculaires |
WO2012028697A1 (fr) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Système de purification par affinité sur la base d'une complémentation de brin de donneur |
US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
EP2623119B1 (fr) | 2010-09-30 | 2017-06-14 | Riken | Médicament utilisé dans un procédé de traitement de gliomes, un procédé d'examen de gliomes, un procédé d'administration d'une substance souhaitée à un gliome |
US8497138B2 (en) | 2010-09-30 | 2013-07-30 | Genetix Limited | Method for cell selection |
ES2686550T3 (es) | 2010-10-11 | 2018-10-18 | Biogen International Neuroscience Gmbh | Anticuerpos anti-tau humanos |
US20120093833A1 (en) | 2010-10-13 | 2012-04-19 | Juan Carlos Almagro | Human Oncostatin M Antibodies and Methods of Use |
US9346889B2 (en) | 2010-10-18 | 2016-05-24 | Mediapharma S.R.L. | ErbB3 binding antibody |
CN103561759B (zh) | 2010-10-22 | 2016-10-12 | 西雅图遗传学公司 | 以奥里斯他汀(AURISTATIN)为主的抗体药物结合物与PI3K-AKT mTOR路径抑制剂之间的协同作用 |
AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
ES2654820T3 (es) | 2010-10-25 | 2018-02-15 | Biogen Ma Inc. | Métodos para determinar diferencias en la actividad de la alfa-4-integrina mediante la correlación de las diferencias en los niveles de sVCAM y/o sMAdCAM |
NZ623347A (en) | 2010-10-29 | 2014-07-25 | Daiichi Sankyo Co Ltd | Novel anti-dr5 antibody |
EP2640425A2 (fr) | 2010-11-18 | 2013-09-25 | Beth Israel Deaconess Medical Center, Inc. | Méthodes de traitement de l'obésité par inhibition de la nicotinamide n-méthyltransférase (nnmt) |
WO2012068540A2 (fr) | 2010-11-19 | 2012-05-24 | Toshio Imai | Neutralisation d'anticorps anti-ccl20 |
AU2011332025B2 (en) | 2010-11-23 | 2015-06-25 | The Trustees Of The University Of Pennsylvania | Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof |
AU2011343161B2 (en) | 2010-12-17 | 2017-02-02 | Neurimmune Holding Ag | Human anti-SOD1 antibodies |
WO2012090939A1 (fr) | 2010-12-27 | 2012-07-05 | 国立大学法人名古屋大学 | Méthode d'inhibition du signalement pro-survie faisant intervenir les récepteurs tyrosines kinases dans les cellules cancéreuses |
DK2663580T3 (en) | 2011-01-10 | 2017-03-13 | Ct Atlantic Ltd | COMBINATION THERAPY INCLUDING TUMOR ASSOCIATED ANTI-BINDING ANTIBODIES |
DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
EP3187216B1 (fr) | 2011-01-24 | 2019-08-21 | AbbVie Biotechnology Ltd. | Dispositifs d'injection automatique présentant des surfaces de préhension surmoulées |
WO2012104824A1 (fr) | 2011-02-04 | 2012-08-09 | Ecole polytechnique fédérale de Lausanne (EPFL) | Anticorps thérapeutiques ciblant app-c99 |
WO2012107589A1 (fr) | 2011-02-11 | 2012-08-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement et la prévention des infections à vhc |
WO2012110843A1 (fr) | 2011-02-18 | 2012-08-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour promouvoir la fibrinolyse et la thrombolyse |
US20140044644A1 (en) | 2011-02-21 | 2014-02-13 | University Of Zurich | Ankyrin g and modulators thereof for the treatment of neurodegenerative disorders |
WO2012119999A1 (fr) | 2011-03-07 | 2012-09-13 | F. Hoffmann-La Roche Ag | Moyens et procédés destinés aux tests in vivo d'anticorps thérapeutiques |
JP6385060B2 (ja) | 2011-03-07 | 2018-09-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 治療的に活性な抗体のインビボにおける選択 |
EP2684045B2 (fr) | 2011-03-09 | 2023-03-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes pour caractériser des patients souffrant d'hémolyse |
WO2012125680A1 (fr) | 2011-03-16 | 2012-09-20 | Novartis Ag | Méthodes de traitement de vascularite à l'aide d'un molécule de liaison à l'il-17 |
KR101551555B1 (ko) | 2011-03-17 | 2015-09-08 | 밀테니 비오텍 게앰베하 | Tcr 알파/베타가 고갈된 세포 제제 |
EP2688592A4 (fr) | 2011-03-25 | 2015-07-22 | Baylor Res Inst | Compositions et procédés d'immunisation contre le virus de l'hépatite c |
TW201249867A (en) | 2011-04-01 | 2012-12-16 | Astellas Pharma Inc | Novel anti-human il-23 receptor antibody |
MX345747B (es) | 2011-04-21 | 2017-02-14 | Abbvie Inc | Dispositivo de inyección automático portable. |
PL2703486T3 (pl) | 2011-04-25 | 2018-07-31 | Daiichi Sankyo Company, Limited | Przeciwciało anty-b7-h3 |
MX367097B (es) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
UA117218C2 (uk) | 2011-05-05 | 2018-07-10 | Мерк Патент Гмбх | Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f |
WO2012154889A1 (fr) | 2011-05-09 | 2012-11-15 | The Cleveland Clinic Foundation | Sérum s 100b et ses utilisations |
WO2012163848A1 (fr) | 2011-05-27 | 2012-12-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques destinés au traitement de la maladie de crohn |
EP2530088A1 (fr) | 2011-05-30 | 2012-12-05 | Klinikum rechts der Isar der Technischen Universität München | Supports et procédés de diagnostic et de traitement de la sclérose en plaques |
US20140093514A1 (en) | 2011-06-03 | 2014-04-03 | University Of Zurich | Magea3 binding antibodies |
JP2014524891A (ja) | 2011-06-03 | 2014-09-25 | シーティー アトランティック リミテッド | Magea3結合抗体 |
JP6305919B2 (ja) | 2011-06-06 | 2018-04-04 | プロセナ バイオサイエンシーズ リミテッド | Mcamアンタゴニスト及び治療の方法 |
WO2012172449A1 (fr) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactames convenant comme inhibiteurs des bêta-sécrétases |
US20140120555A1 (en) | 2011-06-20 | 2014-05-01 | Pierre Fabre Medicament | Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer |
DK2723379T3 (en) | 2011-06-23 | 2018-10-15 | Biogen Int Neuroscience Gmbh | ANTI-ALPHA SYNUCLEIN BINDING MOLECULES |
DE202011103324U1 (de) | 2011-07-12 | 2012-01-02 | Nekonal S.A.R.L. | Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten |
GB201112056D0 (en) | 2011-07-14 | 2011-08-31 | Univ Leuven Kath | Antibodies |
WO2013014262A1 (fr) | 2011-07-27 | 2013-01-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de diagnostic et de traitement du syndrome de myhre |
JP5376095B2 (ja) | 2011-08-11 | 2013-12-25 | アステラス製薬株式会社 | 新規抗ヒトngf抗体 |
US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
WO2013024517A1 (fr) | 2011-08-12 | 2013-02-21 | 国立感染症研究所 | Méthode pour le test, la prévention et le traitement d'une maladie infectieuse par aspergillus fumigatus ; et composition |
GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
HUE036177T2 (hu) | 2011-09-19 | 2018-06-28 | Axon Neuroscience Se | TAU-mediált patológia protein alapú terápiája és diagnózisa Alzheimer-betegségben |
GB2495115A (en) * | 2011-09-29 | 2013-04-03 | Oxford Plastic Sys Ltd | Base for supporting temporary fence panels or posts. |
TW201329105A (zh) | 2011-10-04 | 2013-07-16 | Thr Trustees Of Columbia University In The City Of New York | 人類notch1引誘物 |
EP2764118A1 (fr) | 2011-10-05 | 2014-08-13 | University of Bremen | Wnt4 et med12 pour l'utilisation dans le diagnostic et le traitement de maladies tumorales |
WO2013050441A1 (fr) | 2011-10-05 | 2013-04-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et composition pharmaceutique pour l'inhibition ou la prévention de l'agrégation des plaquettes |
WO2013054320A1 (fr) | 2011-10-11 | 2013-04-18 | Tel Hashomer Medical Research Infrastructure And Services Ltd. | Anticorps dirigés contre la molécule d'adhésion cellulaire associée à l'antigène carcino-embryonnaire (ceacam) |
WO2013055911A1 (fr) | 2011-10-14 | 2013-04-18 | Dana-Farber Cancer Institute, Inc. | Biomarqueur znf365/zfp365 pouvant prévoir une réponse anticancéreuse |
JP6466170B2 (ja) | 2011-10-17 | 2019-02-06 | ミネルバ バイオテクノロジーズ コーポレーション | 幹細胞の増殖及び誘導用の培地 |
WO2013057313A1 (fr) | 2011-10-20 | 2013-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de dépistage et de traitement du remodelage cardiaque |
EP2589609A1 (fr) | 2011-11-03 | 2013-05-08 | Pierre Fabre Medicament | Protéine se liant à un antigène et son utilisation pour l'adressage d'un produit pour le traitement du cancer |
EP2782933A1 (fr) | 2011-11-22 | 2014-10-01 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Procédés et compositions pharmaceutiques pour la réduction de l'hyperréactivité dans les voies aériennes |
US9427464B2 (en) | 2011-11-22 | 2016-08-30 | Chiome Bioscience Inc. | Anti-human TROP-2 antibody having an antitumor activity in vivo |
ES2638649T3 (es) | 2011-11-28 | 2017-10-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Composición farmacéutica para su uso en el tratamiento de disfunciones asociadas al envejecimiento |
EP2602621A1 (fr) | 2011-12-08 | 2013-06-12 | Julius-Maximilians-Universität Würzburg | LASP-1, nouveau marqueur urinaire pour la détection du carcinome cellulaire transitionnel |
BR112014014258A2 (pt) * | 2011-12-13 | 2020-10-27 | Nordic Nanovector As. | molécula de anticorpo que se liga a cd37 humano; anticorpo; molécula de dna; vetor de expressão; célula hospedeira; método para produzir um anticorpo; composição farmacêutica; método de esgotamento de células b que expressam cd37 dentre uma população de células; radioimunoconjugado que se liga a cd37 humano; método de tratamento de uma malignidade de célula b; kit para a produção do radioimunoconjugado; e preparação injetável de anticorpo hh1 quimérico ou humanizado para uso no pré-tratamento de uma malignidade de célula b |
WO2013093122A2 (fr) | 2011-12-23 | 2013-06-27 | Phenoquest Ag | Anticorps pour le traitement et le diagnostic de troubles affectifs et de l'anxiété |
FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
WO2013098419A1 (fr) | 2011-12-28 | 2013-07-04 | Immunoqure Ag | Méthode pour fournir des auto-anticorps monoclonaux à spécificité désirée |
US20150216998A1 (en) | 2012-01-01 | 2015-08-06 | Ramot At Tel-Aviv University Ltd. | Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents |
CN108324943B (zh) | 2012-02-10 | 2024-03-08 | 思进股份有限公司 | Cd30+癌症的检测和治疗 |
CN104271122A (zh) | 2012-02-16 | 2015-01-07 | 桑塔鲁斯股份有限公司 | 抗vla1(cd49a)抗体药物组合物 |
KR102051505B1 (ko) | 2012-02-23 | 2019-12-03 | 다이이치 산쿄 유럽 게엠베하 | 방사선 감수성 조절을 위한 her3 억제제 |
US9371391B2 (en) | 2012-02-28 | 2016-06-21 | Astellas Pharma Inc. | Anti-human IL-23 receptor antibody and encoding polynucleotides |
SG10201710574UA (en) | 2012-03-15 | 2018-02-27 | Janssen Biotech Inc | Human anti-cd27 antibodies, methods and uses |
CA2867902C (fr) | 2012-03-20 | 2023-09-26 | Biogen Idec Ma Inc. | Anticorps neutralisant le virus jcv |
TW201345925A (zh) | 2012-03-30 | 2013-11-16 | Daiichi Sankyo Co Ltd | 新穎抗siglec-15抗體 |
TW201343672A (zh) | 2012-03-30 | 2013-11-01 | Daiichi Sankyo Co Ltd | Cdr經修飾之抗siglec-15抗體 |
ES2702278T3 (es) | 2012-04-01 | 2019-02-28 | Technion Res & Dev Foundation | Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión |
CN103382223B (zh) | 2012-04-01 | 2015-06-10 | 上海益杰生物技术有限公司 | 针对表皮生长因子受体隐蔽表位和t细胞抗原的多功能抗体多肽 |
CA2869394A1 (fr) | 2012-04-02 | 2013-10-10 | Gundersen Lutheran Health System, Inc. | Reactifs, procedes, et kits pour la classification du cancer |
SG10201608382QA (en) | 2012-04-09 | 2016-12-29 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
PL2841457T3 (pl) | 2012-04-27 | 2019-09-30 | Daiichi Sankyo Company, Limited | Przeciwciało anty-ROBO4 |
US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
JP6263117B2 (ja) | 2012-05-11 | 2018-01-17 | 公益財団法人微生物化学研究会 | 抗cxadr抗体 |
US9512223B2 (en) | 2012-05-15 | 2016-12-06 | Morphotek, Inc. | Methods for treatment of gastric cancer |
CN105473723A (zh) | 2012-05-18 | 2016-04-06 | 宾夕法尼亚大学托管会 | 亚家族e猿腺病毒a1302、a1320、a1331和a1337及其用途 |
US20150140010A1 (en) | 2012-05-22 | 2015-05-21 | Inserm 9Institut National De La Sante Et De La R- Echerche Medicale) | Methods for diagnosing and treating focal segmental glomerulosclerosis |
MX369626B (es) | 2012-05-24 | 2019-11-13 | Mountgate Group Ltd | Composiciones y metodos relacionados con la prevencion y el tratamiento de infecciones por rabia. |
LT4019041T (lt) | 2012-07-13 | 2023-04-11 | The Trustees Of The University Of Pennsylvania | Toksiškumo, atsirandančio dėl car receptorių priešnavikinio aktyvumo, suvaldymas |
EP2875049B1 (fr) | 2012-07-18 | 2018-12-26 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Procédés de prévention et de traitement de maladie rénale chronique (mrc) |
CN104582717B (zh) | 2012-07-19 | 2018-03-13 | 雷德伍德生物科技股份有限公司 | 对cd22有特异性的抗体及其使用方法 |
AU2013297478B2 (en) | 2012-07-30 | 2018-12-20 | Medical & Biological Laboratories Co., Ltd. | Monoclonal antibody against human midkine |
EP3838923B1 (fr) | 2012-08-24 | 2024-05-01 | The Regents of The University of California | Anticorps et vaccins pour utilisation dans le traitement de cancers ror1 et inhibition des métastases |
TWI595007B (zh) | 2012-09-10 | 2017-08-11 | Neotope Biosciences Ltd | 抗mcam抗體及相關使用方法 |
WO2014042251A1 (fr) | 2012-09-13 | 2014-03-20 | 中外製薬株式会社 | Animal non humain comportant un gène knock-in |
EP2711016A1 (fr) | 2012-09-21 | 2014-03-26 | Covagen AG | Nouvelles molécules de liaison IL-17A et leurs utilisations médicales |
RS57120B1 (sr) | 2012-10-03 | 2018-06-29 | Chiome Bioscience Inc | Anti-humano dlk-1 antitelo koje ima in vivo aktivnost protiv tumora |
EP3677310A1 (fr) | 2012-10-08 | 2020-07-08 | St. Jude Children's Research Hospital | Thérapies fondées sur la régulation de la stabilité et de la fonction des lymphocytes t régulateurs par l'intermédiaire d'un axe neuropiline-1:sémaphorine |
WO2014057687A1 (fr) | 2012-10-11 | 2014-04-17 | 第一三共株式会社 | Conjugué anticorps-médicament |
DE102012020496A1 (de) | 2012-10-18 | 2014-04-24 | Charité - Universitätsmedizin Berlin | Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1 |
JP6272230B2 (ja) | 2012-10-19 | 2018-01-31 | 第一三共株式会社 | 親水性構造を含むリンカーで結合させた抗体−薬物コンジュゲート |
US20150246118A1 (en) | 2012-10-26 | 2015-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
EP3508503B1 (fr) | 2012-11-01 | 2022-11-02 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Anticorps contre la cd269 (bcma) |
AR093357A1 (es) | 2012-11-05 | 2015-06-03 | Pf Medicament | Proteinas de union al antigeno y su utilizacion como producto de direccionamiento para el tratamiento del cancer |
WO2014072416A1 (fr) | 2012-11-08 | 2014-05-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de métastases osseuses |
TW201438736A (zh) | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以dll4拮抗劑治療卵巢癌之方法 |
RS60084B1 (sr) | 2012-12-10 | 2020-05-29 | Biogen Ma Inc | Antitela anti-antigen 2 dendritske ćelije krvi i njihove upotrebe |
US20160185847A1 (en) | 2012-12-17 | 2016-06-30 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Use of monoclonal antibodies for the treatment of inflammation and bacterial infections |
WO2014100602A1 (fr) | 2012-12-20 | 2014-06-26 | Hospital For Special Surgery | Traitement de pathologies dépendant du récepteur de l'egf |
LT2935326T (lt) | 2012-12-21 | 2020-12-10 | Biogen Ma Inc. | Žmogaus antikūnai prieš tau baltymą |
EP2938631B1 (fr) | 2012-12-31 | 2018-12-19 | Neurimmune Holding AG | Anticorps humains recombinants pour la thérapie et la prévention de maladies associées au virus du polyome |
EP2752426A1 (fr) | 2013-01-03 | 2014-07-09 | Covagen AG | Composés de liaison d'albumine de sérum humain et leurs protéines de fusion |
SI2949675T1 (sl) | 2013-01-28 | 2021-08-31 | Evec Inc. | Humanizirano protitelo ANTI-HMGB1 ali njegov antigen-vezavni fragment |
EP2951589A1 (fr) | 2013-02-01 | 2015-12-09 | INSERM - Institut National de la Santé et de la Recherche Médicale | Procédés de prédiction et de prévention d'une métastase dans des cancers du sein triples négatifs |
JP6357113B2 (ja) | 2013-02-08 | 2018-07-11 | 株式会社医学生物学研究所 | ヒトnrg1タンパク質に対する抗体 |
EP2956478A1 (fr) | 2013-02-15 | 2015-12-23 | ESBATech - a Novartis Company LLC | Structure d'accepteur pour greffe cdr |
CN104884471A (zh) | 2013-02-20 | 2015-09-02 | 艾斯巴技术-诺华有限责任公司 | 用于cdr移植的受体框架 |
FR3004184B1 (fr) | 2013-02-26 | 2016-03-18 | Agronomique Inst Nat Rech | Anticorps anti-gluten desamide et utilisations. |
JP6490574B2 (ja) | 2013-02-28 | 2019-03-27 | 国立研究開発法人国立がん研究センター | 不溶性フィブリンに対する抗体 |
JP6218088B2 (ja) | 2013-03-08 | 2017-11-01 | 国立大学法人大阪大学 | ペリオスチンのExon−21部位によりコードされるペプチドに対する抗体及び該抗体を含む炎症関連疾患の予防又は治療用医薬組成物 |
BR112015022587A2 (pt) | 2013-03-13 | 2017-10-24 | Eleven Biotherapeutics Inc | formulações de citocina quimérica para entrega ocular |
US10023608B1 (en) | 2013-03-13 | 2018-07-17 | Amgen Inc. | Protein purification methods to remove impurities |
EP2968550B1 (fr) | 2013-03-14 | 2018-11-14 | Ffe Therapeutics LLC | Compositions et procédés pour le traitement de troubles liés à l'angiogenèse |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
US10035859B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
KR20150128796A (ko) | 2013-03-15 | 2015-11-18 | 바이오젠 엠에이 인코포레이티드 | 항-알파 v 베타 5개 항체를 이용한 급성 신장 손상의 치료 및 예방 |
US10035860B2 (en) | 2013-03-15 | 2018-07-31 | Biogen Ma Inc. | Anti-alpha V beta 6 antibodies and uses thereof |
SG10201708048XA (en) | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
WO2014165524A2 (fr) | 2013-04-01 | 2014-10-09 | The Regents Of The University Of California | Méthodes et compositions pour traiter et prévenir la maladie associée à l'intégrine avβ8 |
WO2014174596A1 (fr) | 2013-04-23 | 2014-10-30 | 株式会社医学生物学研究所 | Anticorps monoclonal fonctionnel dirigé contre le facteur de croissance de type facteur de croissance épidermique se liant à l'héparine |
US9717648B2 (en) | 2013-04-24 | 2017-08-01 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
CN107460201A (zh) | 2013-05-08 | 2017-12-12 | 科济生物医药(上海)有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
EP3159695A3 (fr) | 2013-06-20 | 2017-07-05 | The Trustees of The University of Pennsylvania | Procédé de diagnostic du cancer du pancréas |
WO2015001013A2 (fr) | 2013-07-03 | 2015-01-08 | Immunoqure Ag | Anticorps anti-ifn-alpha humains |
US20160176943A1 (en) | 2013-07-05 | 2016-06-23 | Inserm (Insititut National De La Sante Et De La Recherche Medicale) | Novel alternative splice transcripts for mhc class i related chain alpha (mica) and uses thereof |
WO2015003114A1 (fr) | 2013-07-05 | 2015-01-08 | University Of Washington Through Its Center For Commercialization | Anticorps monoclonal neutralisant la protéine mic soluble pour le traitement du cancer |
JP6380394B2 (ja) | 2013-08-09 | 2018-08-29 | アステラス製薬株式会社 | 新規抗ヒトtslp受容体抗体 |
WO2015036956A1 (fr) | 2013-09-12 | 2015-03-19 | Institut National De La Sante Et De La Recherche Medicale | Méthode de quantification in vitro d'allo-anticorps, d'auto-anticorps et/ou d'anticorps thérapeutiques |
AU2014322988B2 (en) | 2013-09-20 | 2018-12-06 | Westfaelische Wilhelms-Universitaet Muenster | Cell-penetrating bacterial E3-ubiqitin-ligases for use in immunotherapy |
CN105764923A (zh) | 2013-09-24 | 2016-07-13 | 范因斯坦医学研究院 | 对可冷诱导的rna结合蛋白活性进行抑制的肽 |
WO2015048531A1 (fr) | 2013-09-26 | 2015-04-02 | Beth Israel Deaconess Medical Center, Inc. | Inhibition de la sgk1 dans le traitement d'affections cardiaques |
EP3835422A1 (fr) | 2013-09-30 | 2021-06-16 | Daiichi Sankyo Company, Limited | Anticorps anti-lps o11 |
EP3052131B1 (fr) | 2013-10-01 | 2018-12-05 | Mayo Foundation for Medical Education and Research | Procédés de traitement du cancer chez des patients présentant des taux élevés de bim |
JP6509735B2 (ja) | 2013-10-08 | 2019-05-08 | 第一三共株式会社 | 抗fgfr2抗体と他剤の組合せ |
JPWO2015068781A1 (ja) | 2013-11-06 | 2017-03-09 | 国立大学法人大阪大学 | インフルエンザウイルスa型のグループ1に対して広域な中和活性を有する抗体 |
EP3466445A1 (fr) | 2013-11-06 | 2019-04-10 | Janssen Biotech, Inc. | Anticorps anti-ccl17 |
WO2015071701A1 (fr) | 2013-11-15 | 2015-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de cancers du pancréas |
WO2015082446A1 (fr) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Traitement du cancer à l'aide d'un anticorps anti-cdcp1 et d'un taxane |
CN105829534B (zh) | 2013-12-24 | 2021-08-03 | 安斯泰来制药株式会社 | 抗人bdca-2抗体 |
CA2933666C (fr) | 2013-12-25 | 2021-08-03 | Sapporo Medical University | Conjugue anticorps anti-trop2-medicament |
ES2902835T3 (es) | 2014-01-09 | 2022-03-30 | Hadasit Med Res Service | Composiciones celulares mejoradas y métodos para la terapia contra el cáncer |
AU2015204503B2 (en) | 2014-01-13 | 2020-07-09 | Baylor Research Institute | Novel vaccines against HPV and HPV-related diseases |
CN104774264B (zh) | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
KR102362920B1 (ko) | 2014-01-31 | 2022-02-14 | 다이이찌 산쿄 가부시키가이샤 | 항-her2 항체-약물 접합체 |
WO2015124570A1 (fr) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et composition pharmaceutique pour le traitement de l'infection par le virus de la grippe a |
WO2015124588A1 (fr) | 2014-02-18 | 2015-08-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement de maladies induites par la voie de signalisation du complexe nrp-1/obr |
EP2915543B1 (fr) | 2014-03-04 | 2018-05-09 | Albert-Ludwigs-Universität Freiburg | Polypeptides dérivés de enterococcus et leur utilisation pour la vaccination et la génération d'anticorps thérapeutiques |
WO2015140351A1 (fr) | 2014-03-21 | 2015-09-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour renforcer la myélinisation |
US20170174764A1 (en) | 2014-03-27 | 2017-06-22 | Yeda Research And Development Co. Ltd. | T-cell receptor cdr3 peptides and antibodies |
SG11201608309PA (en) | 2014-04-10 | 2016-11-29 | Daiichi Sankyo Co Ltd | Anti-her3 antibody-drug conjugate |
EP3134546A4 (fr) | 2014-04-24 | 2017-12-06 | Dana-Farber Cancer Institute, Inc. | Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire |
PL3134124T3 (pl) | 2014-04-25 | 2019-09-30 | Pierre Fabre Medicament | Koniugat przeciwciało IGF-IR-lek i jego zastosowanie do leczenia raka |
CA2946796C (fr) | 2014-04-25 | 2019-10-22 | Pierre Fabre Medicament | Conjugue anticorps-medicament et son utilisation pour le traitement du cancer |
EP3783033A1 (fr) | 2014-04-25 | 2021-02-24 | Pierre Fabre Medicament | Anticorps igf-1r et son utilisation en tant que véhicule d'adressage pour le traitement du cancer |
MD20160130A2 (ro) | 2014-04-27 | 2017-04-30 | Ccam Biotherapeutics Ltd. | Anticorpi umanizaţi contra CEACAM1 |
US11427647B2 (en) | 2014-04-27 | 2022-08-30 | Famewave Ltd. | Polynucleotides encoding humanized antibodies against CEACAM1 |
US10302653B2 (en) | 2014-05-22 | 2019-05-28 | Mayo Foundation For Medical Education And Research | Distinguishing antagonistic and agonistic anti B7-H1 antibodies |
TWI713453B (zh) | 2014-06-23 | 2020-12-21 | 美商健生生物科技公司 | 干擾素α及ω抗體拮抗劑 |
EP3160493A4 (fr) | 2014-06-26 | 2018-04-11 | Yale University | Compositions et procédés pour réguler la rénalase dans le traitement de certaines maladies et de certains troubles |
CN112979828A (zh) | 2014-07-17 | 2021-06-18 | 恺兴生命科技(上海)有限公司 | 靶向cld18a2的t淋巴细胞及其制备方法和应用 |
EP3169691B1 (fr) | 2014-07-17 | 2020-09-02 | The Trustees Of The University Of Pennsylvania | Procédés permettant d'utiliser des exosomes pour surveiller l'état d'un organe transplanté |
US10517875B2 (en) | 2014-07-23 | 2019-12-31 | Mayo Foundation for Medical Engineering and Research | Targeting DNA-PKcs and B7-H1 to treat cancer |
KR102594327B1 (ko) | 2014-09-30 | 2023-10-27 | 뉴리뮨 홀딩 아게 | 인간-유래의 항-디펩티드 반복체(dpr) 항체 |
EP3201226A2 (fr) | 2014-10-03 | 2017-08-09 | Massachusetts Institute of Technology | Anticorps qui se lient à la glycoprotéine du virus ébola et utilisations associés |
CA2963091A1 (fr) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Biomarqueurs a base d'angiopoietine -2 utilises pour la prediction de la reponse de point de controle anti-immunitaire |
JP6941561B2 (ja) | 2014-10-09 | 2021-09-29 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 免疫障害を処置するための複数の可変il−2用量レジメン |
ES2832802T3 (es) | 2014-11-21 | 2021-06-11 | Univ Maryland | Sistemas de administración dirigida del particulado específico de una estructura |
WO2016087889A1 (fr) | 2014-12-03 | 2016-06-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques utilisant des orexines (oxa, oxb) pour le traitement de cancers de la prostate |
WO2016128523A1 (fr) | 2015-02-12 | 2016-08-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour prédire la réactivité d'un patient atteint d'une maladie hématologique maligne à un traitement par chimiothérapie et procédés de traitement de ces maladies |
AU2016229238B2 (en) | 2015-03-06 | 2022-06-02 | Dana-Farber Cancer Institute, Inc. | PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers |
EP3067062A1 (fr) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combinaison de tasquinimod ou d'un sel pharmaceutiquement acceptable de celui-ci et d'un inhibiteur de pd1 et/ou de pdl1, destinée à être utilisée comme médicament |
US20180092977A1 (en) | 2015-03-18 | 2018-04-05 | The Johns Hopkins University | Novel monoclonal antibody inhibitors targeting potassium channel kcnk9 |
US10426818B2 (en) | 2015-03-24 | 2019-10-01 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Method and pharmaceutical composition for use in the treatment of diabetes |
US10214591B1 (en) | 2015-04-03 | 2019-02-26 | Alienor Farma | Monoclonal antibody to human line-1 ORF2 protein and method for early detection of transforming cells in pre-neoplastic tissues of a human subject |
ES2841437T3 (es) | 2015-04-13 | 2021-07-08 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de enfermedades hemorrágicas |
JP2018519248A (ja) | 2015-04-22 | 2018-07-19 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Th17媒介性疾患の処置のための方法及び医薬組成物 |
NZ737400A (en) | 2015-06-01 | 2019-09-27 | Medigene Immunotherapies Gmbh | T cell receptor library |
JP2018517712A (ja) | 2015-06-01 | 2018-07-05 | メディジーン イミュノテラピーズ ゲーエムベーハー | T細胞受容体特異的抗体 |
WO2016193300A1 (fr) | 2015-06-01 | 2016-12-08 | Medigene Immunotherapies Gmbh | Procédé de production d'anticorps dirigés contre un récepteur de lymphocytes t |
CN107922457B (zh) | 2015-06-19 | 2022-05-13 | 森托瑞恩生物制药公司 | 用于控制药物释放的递送系统 |
WO2016210241A1 (fr) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancérothérapie ciblant la tétraspanine 33 (tspan33) dans des cellules myéloïdes suppressives |
IL290959B2 (en) | 2015-06-29 | 2023-04-01 | Daiichi Sankyo Co Ltd | Preparations containing antibody-drug conjugates and methods for their production |
CA2994825A1 (fr) | 2015-08-05 | 2017-02-09 | Janssen Biotech, Inc. | Anticorps anti-cd154 et procedes d'utilisation correspondant |
WO2017046335A1 (fr) | 2015-09-18 | 2017-03-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Récepteurs de lymphocytes t (tcr) et leurs utilisations pour le diagnostic et le traitement du diabète |
DK3353196T3 (da) | 2015-09-22 | 2023-02-20 | Inst Nat Sante Rech Med | Polypeptider, der er i stand til at inhibere bindingen mellem leptin og neuropilin-1 |
AU2016325858B2 (en) | 2015-09-24 | 2022-05-26 | Daiichi Sankyo Company, Limited | Anti-GARP antibody |
WO2017059196A2 (fr) | 2015-09-30 | 2017-04-06 | Janssen Biotech, Inc. | Anticorps antagonistes se liant spécifiquement au cd40 humain et procédés d'utilisation |
JP6857360B2 (ja) | 2015-10-08 | 2021-04-14 | 国立大学法人東海国立大学機構 | キメラ抗原受容体を発現する遺伝子改変t細胞の調製方法 |
WO2017064716A1 (fr) | 2015-10-13 | 2017-04-20 | Rappaport Family Institute For Research | Anticorps monoclonaux neutralisant l'héparanase |
EP3362082A1 (fr) | 2015-10-16 | 2018-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de maladies inflammatoires auto-immunes |
MX2018005070A (es) | 2015-10-26 | 2018-09-06 | Pf Medicament | Composición para el tratamiento de cáncer con expresión del igf-1r. |
US10875923B2 (en) | 2015-10-30 | 2020-12-29 | Mayo Foundation For Medical Education And Research | Antibodies to B7-H1 |
ITUB20155272A1 (it) | 2015-11-02 | 2017-05-02 | Scuola Normale Superiore | Intracellular antibody |
US20180320136A1 (en) | 2015-11-03 | 2018-11-08 | GlycoMimitics, Inc. | Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same |
BR112018008891A8 (pt) | 2015-11-03 | 2019-02-26 | Janssen Biotech Inc | anticorpos que se ligam especificamente a pd-1 e tim-3 e seus usos |
ITUB20155097A1 (it) | 2015-11-05 | 2017-05-05 | Biouniversa Srl | Anticorpi umanizzati anti-BAG3 |
US10829562B2 (en) | 2015-12-10 | 2020-11-10 | Katholieke Universiteit Leuven | Haemorrhagic disorder due to ventricular assist device |
BR112018012344A2 (pt) | 2015-12-17 | 2018-12-04 | Janssen Biotech Inc | anticorpos que se ligam especificamente a hla-dr e seus usos |
GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
KR20200100858A (ko) | 2015-12-23 | 2020-08-26 | 메디진 이뮤노테라피스 게엠바하 | 수지상 세포 조성물 |
KR102430893B1 (ko) | 2015-12-31 | 2022-08-09 | 프로가스트린 에 캔서스 에스.에이 알.엘. | 식도암을 검출 및 치료하기 위한 조성물 및 방법 |
WO2017114975A1 (fr) | 2015-12-31 | 2017-07-06 | Progastrine Et Cancers S.À R.L. | Compositions et méthodes pour dépister et traiter le cancer gastrique |
AU2017204682B2 (en) | 2015-12-31 | 2021-07-29 | Progastrine Et Cancers S.À R.L. | Compositions and methods for detecting and treating ovarian cancer |
EP3202788A1 (fr) | 2016-02-05 | 2017-08-09 | MediaPharma S.r.l. | Anticorps à liaison d'endosialin |
EP3205663A1 (fr) | 2016-02-15 | 2017-08-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Moyens et procédés permettant d'inhiber l'expression génique |
WO2017140684A2 (fr) | 2016-02-15 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement d'un dysfonctionnement cognitif postopératoire |
US10906987B2 (en) | 2016-03-01 | 2021-02-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Antibodies specific to human poliovirus receptor (PVR) |
WO2017153432A1 (fr) | 2016-03-07 | 2017-09-14 | Pierre Fabre Medicament | Nouveau procédé universel pour capturer et analyser des adc pour la caractérisation de la distribution de médicament et du rapport médicament-anticorps dans des échantillons biologiques |
WO2017156263A1 (fr) | 2016-03-09 | 2017-09-14 | Memorial Sloan-Kettering Cancer Center | Enigma et cdh18 en tant que diagnostic compagnon pour des inhibiteurs de cdk4 |
KR102408161B1 (ko) | 2016-03-15 | 2022-06-13 | 엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔 (인쎄름) | 대상체가 췌관 선암을 앓을 위험을 평가하기 위한 초기 및 비 침습적 방법 및 이러한 질환의 치료 방법 |
WO2017158396A1 (fr) | 2016-03-16 | 2017-09-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibiteurs de cytidine désaminase pour le traitement du cancer du pancréas |
EP3433615A1 (fr) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Procédés de diagnostic et de traitement de lentigos séniles |
CA3007135A1 (fr) | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Nouveaux anticorps contre pd-l1 |
SI3436461T1 (sl) | 2016-03-28 | 2024-03-29 | Incyte Corporation | Pirolotriazinske spojine kot tam-inhibitorji |
ITUA20162242A1 (it) | 2016-04-01 | 2017-10-01 | St Biochimico Italiano Giovanni Lorenzini Spa | Un nuovo anticorpo anti-erbb2 |
LT3445785T (lt) | 2016-04-18 | 2022-10-10 | Faron Pharmaceuticals Oy | Humanizuoti anti clever-1 antikūnai ir jų naudojimas |
EP3452512B1 (fr) | 2016-05-03 | 2023-03-08 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Procédés et compositions pharmaceutiques pour le traitement de lésion de tissu |
CN109219660B (zh) | 2016-05-11 | 2023-01-06 | 美国安进公司 | 使用谷氨酰胺合成酶基因内互补载体直接选择表达高水平异聚蛋白的细胞 |
JP2019516799A (ja) | 2016-05-20 | 2019-06-20 | カール、クリストフKARL, Christoph | 骨代謝の障害および低カルシウム血症などの治療誘発性副作用の処置および/または予防に適した、抗rankl抗体、カルシウムおよびビタミンdを含む薬学的組成物 |
WO2017202814A1 (fr) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de troubles neuropathologiques caractérisés par une perte de neurones corticaux |
WO2017202813A1 (fr) | 2016-05-24 | 2017-11-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques destinés au traitement d'infections pulmonaires bactériennes |
AU2017276706A1 (en) | 2016-06-07 | 2019-01-03 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
GB201610198D0 (en) | 2016-06-10 | 2016-07-27 | Ucb Biopharma Sprl | Anti-ige antibodies |
ES2883182T3 (es) | 2016-07-06 | 2021-12-07 | Prothena Biosciences Ltd | Ensayo para la detección de alfa-sinucleína total y fosforilada en S129 |
JP2018035137A (ja) | 2016-07-13 | 2018-03-08 | マブイミューン ダイアグノスティックス エイジーMabimmune Diagnostics Ag | 新規な抗線維芽細胞活性化タンパク質(fap)結合薬剤およびその使用 |
US20190330318A1 (en) | 2016-07-25 | 2019-10-31 | Biogen Ma Inc. | Anti-hspa5 (grp78) antibodies and uses thereof |
US20190271702A1 (en) | 2016-07-28 | 2019-09-05 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods of treatement of cancer disease by targetting tumor associated macrophage |
EP3497126A4 (fr) | 2016-08-12 | 2020-04-08 | Janssen Biotech, Inc. | Anticorps de membres de la superfamille anti-tnfr modifiés par fc ayant une activité agoniste améliorée et leurs procédés d'utilisation |
KR102587941B1 (ko) | 2016-08-12 | 2023-10-11 | 얀센 바이오테크 인코포레이티드 | 향상된 효능작용 및 이펙터 기능을 갖는 조작된 항체 및 다른 Fc-도메인 함유 분자 |
AU2017332721B2 (en) | 2016-09-20 | 2023-11-09 | Sara BUHRLAGE | Compositions and methods for identification, assessment, prevention, and treatment of AML using USP10 biomarkers and modulators |
JPWO2018066626A1 (ja) | 2016-10-07 | 2019-07-18 | 第一三共株式会社 | 抗her2抗体−薬物コンジュゲート投与による耐性癌の治療 |
EP3527225A4 (fr) | 2016-10-12 | 2020-06-10 | Daiichi Sankyo Company, Limited | Composition contenant un anticorps anti-robo4 et un autre agent |
CU20190036A7 (es) | 2016-10-13 | 2019-11-04 | Massachusetts Inst Technology | Anticuerpos que se unen a la proteína de envoltura del virus zika |
IT201600111877A1 (it) | 2016-11-07 | 2018-05-07 | Biouniversa Srl | Anti-BAG3 antibodies in combination with inhibitors of immune check-point for therapeutic use |
MY195529A (en) | 2016-11-18 | 2023-01-30 | Astellas Pharma Inc | Novel Anti-Human MUC1 Antibody Fab Fragment |
CN110049779A (zh) | 2016-12-12 | 2019-07-23 | 第一三共株式会社 | 抗体-药物缀合物和免疫检查点抑制剂的组合 |
EP3556773A4 (fr) | 2016-12-13 | 2020-08-19 | Astellas Pharma Inc. | Anticorps anti-cd73 humain |
JP2020514256A (ja) | 2016-12-15 | 2020-05-21 | ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ,リミテッド | 抗pcnaモノクローナル抗体及びその使用 |
CA3048174A1 (fr) | 2016-12-22 | 2018-06-28 | Daiichi Sankyo Company, Limited | Anticorps anti-cd3 et molecule contenant ledit anticorps |
US20180179490A1 (en) | 2016-12-27 | 2018-06-28 | Miltenyi Biotec Gmbh | CELL COMPOSITION DEPLETED FROM TCRab and CD45RA POSITIVE CELLS |
WO2018129284A1 (fr) | 2017-01-05 | 2018-07-12 | The Johns Hopkins University | Développement de nouveaux anticorps monoclonaux reconnaissant l'antigène membranaire spécifique de la prostate (psma) humain |
CA3050668C (fr) | 2017-01-17 | 2023-08-15 | Daiichi Sankyo Company, Limited | Anticorps anti-gpr20 et conjugue anticorps-medicament anti-gpr20 |
WO2018140510A1 (fr) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Composition et méthodes de traitement d'un accident vasculaire cérébral et d'autres troubles du snc |
AU2018218753A1 (en) | 2017-02-07 | 2019-09-26 | Daiichi Sankyo Company, Limited | Anti-GPRC5D antibody and molecule containing same |
EP3363459A1 (fr) | 2017-02-17 | 2018-08-22 | Alexander Klimka | Polypeptides épitopes de s. aureus et anticorps anticorps monoclonaux respectifs pour le traitement d'infections et le diagnostic immunitaire |
US11623953B2 (en) | 2017-02-27 | 2023-04-11 | Caerus Therapeutics, Inc. | Antibody constructs and methods of treating cancer |
JP7181181B2 (ja) | 2017-02-28 | 2022-11-30 | 第一三共株式会社 | 抗her3抗体-薬物コンジュゲート投与によるegfr-tki抵抗性の非小細胞肺癌の治療方法 |
CN110753702B (zh) | 2017-03-15 | 2022-09-20 | 清华大学 | 抗trkb抗体 |
JOP20180021A1 (ar) | 2017-03-16 | 2019-01-30 | Janssen Biotech Inc | الأجسام المضادة لتكتلات خيوط بروتين تاو (tau) الحلزونية المزدوجة واستخداماتها |
WO2018167283A1 (fr) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique |
US11879014B2 (en) | 2017-03-17 | 2024-01-23 | Tusk Therapeutics Ltd. | Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody |
TWI782000B (zh) | 2017-03-30 | 2022-11-01 | 日商第一三共股份有限公司 | 抗gpr20抗體、其製造方法及其應用 |
CA3058263C (fr) | 2017-03-30 | 2023-08-01 | Ecs-Progastrin Sa | Compositions et procedes pour la detection du cancer de la prostate |
EP3602061B1 (fr) | 2017-03-30 | 2022-07-20 | ECS-Progastrin SA | Compositions et méthodes de détection du cancer du poumon |
US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
WO2018185516A1 (fr) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques destinées à traiter une toxicité cardiovasculaire induite par une thérapie anticancéreuse |
US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
WO2018189403A1 (fr) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques destinées au traitement du cancer |
CN111201034A (zh) | 2017-05-11 | 2020-05-26 | 西托戴恩股份有限公司 | 涉及施用抗ccr5受体试剂的治疗或预防移植物抗宿主病的方法 |
TW202330036A (zh) | 2017-05-15 | 2023-08-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
CA3065516A1 (fr) | 2017-06-05 | 2018-12-13 | Janssen Biotech, Inc. | Anticorps se liant specifiquement a pd-1 et leurs methodes d'utilisation |
US11820822B2 (en) | 2017-06-06 | 2023-11-21 | Dana-Farber Cancer Institute, Inc. | Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways |
WO2019005503A1 (fr) | 2017-06-29 | 2019-01-03 | Rutgers, The State University Of New Jersey | Compositions et procédés ciblant la signalisation g12 en vue d'une thérapie bronchodilatatrice |
CN110913905A (zh) | 2017-06-30 | 2020-03-24 | 国立大学法人北海道大学 | 不产生生长障碍的小儿骨质疏松症治疗药 |
TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類CEACAM5抗體Fab片段 |
EP3655031A1 (fr) | 2017-07-21 | 2020-05-27 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Compositions immunogènes de neisseria meningitidis |
TW202402805A (zh) | 2017-07-27 | 2024-01-16 | 日商第一三共股份有限公司 | 抗cd147抗體、醫藥組成物、該等之用途及抗cd147抗體之製造方法 |
EP3658582A1 (fr) | 2017-07-28 | 2020-06-03 | Intrepida Bio, Inc. | Anticorps anti-bag3 utilisés en tant que réactif thérapeutique dans des maladies cardiovasculaires |
WO2019025299A1 (fr) | 2017-07-31 | 2019-02-07 | F. Hoffmann-La Roche Ag | Procédé d'humanisation à base de structure tridimensionnelle |
EP3444272A1 (fr) | 2017-08-17 | 2019-02-20 | International-Drug-Development-Biotech | Traitement de cancers positifs ck8 en relation avec le statut du gène kras |
KR20200039783A (ko) | 2017-08-23 | 2020-04-16 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Cxcr5에 결합하는 키메라 항원 수용체 및 car-t 세포 |
BR112020003474A2 (pt) | 2017-08-23 | 2020-10-20 | Daiichi Sankyo Company, Limited | composição farmacêutica, e, método para produzir uma composição farmacêutica |
KR20200041993A (ko) | 2017-08-31 | 2020-04-22 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 개량 제조 방법 |
IL272964B2 (en) | 2017-08-31 | 2024-02-01 | Daiichi Sankyo Co Ltd | Production method for antibody-drug conjugates |
US10610585B2 (en) | 2017-09-26 | 2020-04-07 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for treating and preventing HIV |
CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
US20200345800A1 (en) | 2017-10-03 | 2020-11-05 | Tokyo Metropolitan Institute Of Medical Science | Medication for influenza |
CN111447952A (zh) | 2017-10-05 | 2020-07-24 | 第一三共株式会社 | 用于细胞毒性t细胞耗竭的组合物 |
KR101966362B1 (ko) | 2017-10-20 | 2019-04-05 | 주식회사 녹십자 | 항-msln 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
CN111587123A (zh) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
IL305268A (en) | 2017-11-30 | 2023-10-01 | Centurion Biopharma Corp | Maytansinoid-based drug delivery systems |
EP3717503B1 (fr) | 2017-11-30 | 2023-11-08 | LadRx Corporation | Promédicaments se liant à l'albumine de dérivés d'auristatine e |
WO2019106126A1 (fr) | 2017-12-01 | 2019-06-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Modulateurs mdm2 pour le diagnostic et le traitement du liposarcome |
PT3720879T (pt) | 2017-12-05 | 2022-07-13 | Progastrine Et Cancers S A R L | Terapia de combinação entre anticorpo anti-progastrina e imunoterapia para tratar o cancro |
WO2019121872A1 (fr) | 2017-12-20 | 2019-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de diagnostic et de traitement du cancer du foie |
US20190225689A1 (en) | 2018-01-22 | 2019-07-25 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-pd-1 antibodies |
WO2019145537A1 (fr) | 2018-01-26 | 2019-08-01 | Ecs-Progastrin Sa | Combinaison de la détection de progastrine avec d'autres biomarqueurs du cancer dans le diagnostic du cancer |
EP3752252A4 (fr) | 2018-02-12 | 2021-11-17 | Hadasit Medical Research Services and Development Ltd. | Modulation de variants d'épissage de slamf6 pour le traitement du cancer |
WO2019158512A1 (fr) | 2018-02-13 | 2019-08-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes pour le pronostic et le traitement du glioblastome |
EP3759492A1 (fr) | 2018-02-27 | 2021-01-06 | ECS-Progastrin SA | Progastrine en tant que biomarqueur pour l'immunothérapie |
CN112384515A (zh) | 2018-02-27 | 2021-02-19 | 因赛特公司 | 作为a2a/a2b抑制剂的咪唑并嘧啶和三唑并嘧啶 |
JP7125979B2 (ja) | 2018-03-05 | 2022-08-25 | 学校法人 埼玉医科大学 | 異所性骨化の治療又は予防のための医薬組成物 |
WO2019185683A1 (fr) | 2018-03-28 | 2019-10-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement du cancer |
EP3775908A1 (fr) | 2018-04-13 | 2021-02-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de prédiction de l'évolution et du traitement de patients souffrant d'un cancer de la prostate ou d'un cancer du sein |
WO2019201995A1 (fr) | 2018-04-20 | 2019-10-24 | Medizinische Hochschule Hannover | Récepteur antigénique chimérique et lymphocytes t-car se liant à l'antigène du virus de l'herpès |
WO2019207066A1 (fr) | 2018-04-26 | 2019-10-31 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions destinés au traitement du syndrome de sjögren |
WO2019211370A1 (fr) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement du cancer |
WO2019211369A1 (fr) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés et compositions pharmaceutiques pour le traitement du cancer |
JP2021522801A (ja) | 2018-05-09 | 2021-09-02 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミテッド | ヒトネクチン4に特異的な抗体 |
BR112020023041A2 (pt) | 2018-05-11 | 2021-02-09 | Astellas Pharma Inc. | ácido nucleico para tratar alergia a ácaros |
BR112020023031A2 (pt) | 2018-05-11 | 2021-02-09 | Astellas Pharma Inc. | ácido nucleico para tratar alergia a crustáceo |
JP7360766B2 (ja) | 2018-05-17 | 2023-10-13 | アステラス製薬株式会社 | 抗ヒトMUC1抗体Fabフラグメント、ペプチドリンカー及び/又は配位子を含む複合体 |
MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
MA52772A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Anticorps anti-tmeff2 monospécifiques et multispécifiques et leurs utilisations |
MA52777A (fr) | 2018-05-24 | 2021-04-14 | Janssen Biotech Inc | Agents de liaison psma et utilisations correspondantes |
EA202092847A1 (ru) | 2018-05-24 | 2021-04-20 | Янссен Байотек, Инк. | Антитела к cd3 и их применение |
BR112020024061A2 (pt) | 2018-05-28 | 2021-02-17 | Daiichi Sankyo Company, Limited | agente terapêutico para câncer com her2 mutado |
UY38247A (es) | 2018-05-30 | 2019-12-31 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
JP6790307B2 (ja) | 2018-05-31 | 2020-11-25 | 第一三共株式会社 | 抗ヒトtlr7抗体 |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
WO2019234099A1 (fr) | 2018-06-06 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de diagnostic, de prédiction du résultat et de traitement d'un patient souffrant d'insuffisance cardiaque à fraction d'éjection préservée |
WO2019234221A1 (fr) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de stratification et de traitement d'un patient souffrant de leucémie lymphoïde chronique |
KR20210030366A (ko) | 2018-06-20 | 2021-03-17 | 인사이트 코포레이션 | 항-pd-1 항체 및 이의 용도 |
TW202016144A (zh) | 2018-06-21 | 2020-05-01 | 日商第一三共股份有限公司 | 包括cd3抗原結合片段之組成物及其用途 |
CN117771250A (zh) | 2018-06-29 | 2024-03-29 | 因赛特公司 | Axl/mer抑制剂的制剂 |
WO2020007898A1 (fr) | 2018-07-04 | 2020-01-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pour le traitement d'une lésion cérébrale ou d'une maladie neurodégénérative |
KR20210038904A (ko) | 2018-07-25 | 2021-04-08 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘쥬게이트의 효과적인 제조 방법 |
KR20210040059A (ko) | 2018-07-27 | 2021-04-12 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 콘주게이트의 약물 부위를 인식하는 단백질 |
WO2020022499A1 (fr) | 2018-07-27 | 2020-01-30 | 国立大学法人大阪大学 | Composition pour l'inhibition du vieillissement, la prévention, l'atténuation ou le traitement de maladies liées à l'âge, ou le prolongement de la durée de vie |
CA3108044A1 (fr) | 2018-07-31 | 2020-02-06 | Daiichi Sankyo Company, Limited | Traitement d'une tumeur cerebrale metastatique par administration d'un conjugue anticorps-medicament |
JP7458981B2 (ja) | 2018-08-06 | 2024-04-01 | 第一三共株式会社 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
CN112714649A (zh) | 2018-09-06 | 2021-04-27 | 第一三共株式会社 | 新型环状二核苷酸衍生物及其抗体药物偶联物 |
TW202024133A (zh) | 2018-09-20 | 2020-07-01 | 日商第一三共股份有限公司 | 利用投予抗her3抗體-藥物結合物之her3突變癌之治療 |
WO2020059847A1 (fr) | 2018-09-21 | 2020-03-26 | 国立大学法人 東京医科歯科大学 | Anticorps monoclonal humain se fixant spécifiquement a hmgb1 humain, et composition pharmaceutique pour le traitement ou la prévention de la maladie d'alzheimer contenant ledit anticorps monoclonal humain |
CA3113378C (fr) | 2018-09-27 | 2024-01-02 | Pierre Fabre Medicament | Lieurs a base de sulfomaleimide et conjugues correspondants |
US20220048966A1 (en) | 2018-09-28 | 2022-02-17 | Pierre Fabre Medicament | New immunocytokines for the treatment of cancer |
SG11202103670XA (en) | 2018-10-10 | 2021-05-28 | Astellas Pharma Inc | Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex |
UY38407A (es) | 2018-10-15 | 2020-05-29 | Novartis Ag | Anticuerpos estabilizadores de trem2 |
WO2020079164A1 (fr) | 2018-10-18 | 2020-04-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinaison d'un antagoniste big-h3 et d'un inhibiteur de point de contrôle immunitaire pour le traitement d'une tumeur solide |
JOP20210093A1 (ar) | 2018-10-31 | 2023-01-30 | Astellas Pharma Inc | جسم مضاد fn14 غير متوافق مع الإنسان |
EP3880706A1 (fr) | 2018-11-12 | 2021-09-22 | MediaPharma S.r.l. | Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3 |
JP7401456B2 (ja) | 2018-11-14 | 2023-12-19 | 第一三共株式会社 | 抗cdh6抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
SG11202106248XA (en) | 2018-12-11 | 2021-07-29 | Daiichi Sankyo Co Ltd | Combination of antibody-drug conjugate with parp inhibitor |
WO2020132560A2 (fr) | 2018-12-21 | 2020-06-25 | Aim Immunotech Inc. | Compositions et méthodes pour cancérothérapie |
EP3903828A4 (fr) | 2018-12-21 | 2022-10-05 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de kinase |
KR20210113202A (ko) | 2019-01-07 | 2021-09-15 | 아스텔라스세이야쿠 가부시키가이샤 | 배위자, 스페이서, 펩티드 링커 및 생물 분자를 포함하는 복합체 |
TW202043256A (zh) | 2019-01-10 | 2020-12-01 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
WO2020144697A1 (fr) | 2019-01-13 | 2020-07-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anticorps spécifiques à la nectine-2 humaine |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
US20220125754A1 (en) | 2019-01-29 | 2022-04-28 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Treating the causative agent in adhesiogenesis |
EP3924386A4 (fr) | 2019-02-13 | 2023-01-04 | The Brigham & Women's Hospital, Inc. | Anticorps de type adressine anti-ganglions lymphatiques périphériques et leurs utilisations |
WO2020178193A1 (fr) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthode de traitement de la sarcoïdose |
US20220154153A1 (en) | 2019-03-22 | 2022-05-19 | Université de Paris | New inhibitors of lrrk2/pp1 interaction |
TW202102225A (zh) | 2019-03-25 | 2021-01-16 | 日商第一三共股份有限公司 | 抗her2抗體-吡咯并苯二氮呯衍生物結合物 |
TW202102228A (zh) | 2019-03-25 | 2021-01-16 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物結合物 |
US20220154191A1 (en) | 2019-03-25 | 2022-05-19 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Enhancement of cytolytic t-cell activity by inhibiting ebag9 |
WO2020196712A1 (fr) | 2019-03-27 | 2020-10-01 | 第一三共株式会社 | Combinaison d'un conjugué anticorps-dérivé de pyrrolobenzodiazépine et d'un inhibiteur de parp |
KR20210144767A (ko) | 2019-04-01 | 2021-11-30 | 치오메 바이오사이언스 가부시키가이샤 | 암 치료용 의약 |
AU2020253449A1 (en) | 2019-04-02 | 2021-11-18 | Kenjockety Biotechnology, Inc. | Efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto |
CA3136888A1 (fr) | 2019-04-19 | 2020-10-22 | Janssen Biotech, Inc. | Methodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3 |
US20220289854A1 (en) | 2019-04-30 | 2022-09-15 | Dana-Farber Cancer Institute, Inc. | Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents |
WO2020229546A1 (fr) | 2019-05-14 | 2020-11-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lymphocytes t régulateurs ciblés par un agent de blocage alpha de la lymphotoxine et leurs utilisations |
US20230270870A1 (en) | 2019-05-29 | 2023-08-31 | Daiichi Sankyo Company, Limited | Dosage of an antibody-drug conjugate |
WO2020261093A1 (fr) | 2019-06-24 | 2020-12-30 | Novartis Ag | Schéma posologique et polythérapies pour des anticorps multispécifiques ciblant un antigène de maturation des lymphocytes b |
UY38803A (es) | 2019-07-26 | 2021-01-29 | Janssen Biotech Inc | Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y usos de las mismas |
US20220267453A1 (en) | 2019-07-26 | 2022-08-25 | Saitama Medical University | Antibody recognizing extracellular region of alk2/acvr1 |
WO2021019706A1 (fr) | 2019-07-31 | 2021-02-04 | 国立大学法人信州大学 | Procédé de fabrication de population cellulaire contenant des cellules immunitaires d'expression de récepteur antigénique chimérique |
EP4007602A1 (fr) | 2019-08-01 | 2022-06-08 | Incyte Corporation | Schéma posologique pour un inhibiteur d'ido |
BR112022001037A2 (pt) | 2019-08-02 | 2022-06-07 | Cytodyn Inc | Métodos para tratamento ou prevenção de cânceres envolvendo a administração de agentes receptores anti-ccr5 |
CN114555637A (zh) | 2019-08-12 | 2022-05-27 | 比昂生物制剂公司 | 针对ilt2的抗体及其用途 |
EP3792632A1 (fr) | 2019-09-16 | 2021-03-17 | Vito NV | Marqueurs d'immunothérapie |
TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與entpd2抗體之組合療法 |
JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Entpd2抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
EP4034151A1 (fr) | 2019-09-27 | 2022-08-03 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Utilisation d'inhibiteurs d'hormone antimüllerienne pour le traitement du cancer |
EP4034160A1 (fr) | 2019-09-27 | 2022-08-03 | Janssen Biotech, Inc. | Anticorps anti-ceacam et leurs utilisations |
EP4049675A4 (fr) | 2019-10-25 | 2023-11-22 | Daiichi Sankyo Company, Limited | Combinaison d'anticorps anti-garp et d'immunorégulateur |
CA3163339A1 (fr) | 2019-11-15 | 2021-05-20 | Pliant Therapeutics, Inc. | Compositions et methodes pour l'activation d'integrines |
CR20220220A (es) | 2019-11-18 | 2022-09-20 | Janssen Biotech Inc | Vacunas basadas en calr y jak2 mutantes y sus usos |
PE20221325A1 (es) * | 2019-12-10 | 2022-09-09 | Ccoa Therapeutics Inc | Anticuerpos anti-glicoproteina ib alfa humanizada (gpibalpha) |
JP2023509373A (ja) | 2019-12-20 | 2023-03-08 | ノヴァロック バイオセラピューティクス, リミテッド | 抗インターロイキン-23 p19抗体およびそれの使用方法 |
MX2022008208A (es) | 2020-01-03 | 2022-10-21 | Incyte Corp | Terapia de combinación que comprende inhibidores de a2a/a2b y proteína de muerte programada 1 /ligando de muerte programada 1 (pd-1/pdl1). |
WO2021140173A1 (fr) | 2020-01-10 | 2021-07-15 | Biouniversa S.R.L. | Méthodes et utilisations pour le traitement de tumeurs fibreuses solides avec des inhibiteurs de bags |
US20230070181A1 (en) | 2020-02-05 | 2023-03-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of cancer disease by targeting an epigenetic factor |
TW202140012A (zh) | 2020-02-12 | 2021-11-01 | 比利時商健生藥品公司 | 用於治療尿路上皮癌的fgfr酪胺酸激酶抑制劑和抗pd1藥劑 |
TW202144389A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在多發性骨髓瘤中表現之新抗原及其用途 |
TW202144388A (zh) | 2020-02-14 | 2021-12-01 | 美商健生生物科技公司 | 在卵巢癌中表現之新抗原及其用途 |
WO2021175924A1 (fr) | 2020-03-03 | 2021-09-10 | Active Biotech Ab | Tasquinimod ou sel pharmaceutiquement acceptable de celui-ci destiné à être utilisé en polythérapie |
IL296065A (en) | 2020-03-06 | 2022-10-01 | Incyte Corp | Combined treatment including axl/mer and pd-1/pd-l1 inhibitors |
MX2022009597A (es) | 2020-03-06 | 2022-09-02 | Daiichi Sankyo Co Ltd | Conjugado de anticuerpo-farmaco que incluye derivado de dinucleotido ciclico novedoso. |
JP2023517889A (ja) | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | NPM1c陽性がんの免疫療法のための組成物および方法 |
PE20230001A1 (es) | 2020-03-13 | 2023-01-05 | Janssen Biotech Inc | Materiales y metodos para la union de siglec-3/cd33 |
JPWO2021200131A1 (fr) | 2020-03-30 | 2021-10-07 | ||
US11045546B1 (en) | 2020-03-30 | 2021-06-29 | Cytodyn Inc. | Methods of treating coronavirus infection |
EP3889183A1 (fr) | 2020-04-01 | 2021-10-06 | Pierre Fabre Medicament | Complexe de protéine comprenant une immunocytokine |
AU2021253899A1 (en) | 2020-04-06 | 2022-11-17 | University Of Rijeka Faculty Of Medicine | Antibodies to NKp46 and constructs thereof for treatment of cancers and infections |
EP4151655A1 (fr) | 2020-05-14 | 2023-03-22 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Anticorps anti-cd25, fragments de liaison à l'antigène associés et utilisations médicales associées |
WO2021233962A1 (fr) | 2020-05-19 | 2021-11-25 | Institut Curie | Méthodes de diagnostic et de traitement du syndrome de libération de cytokines |
CA3184189A1 (fr) | 2020-05-27 | 2021-12-02 | Janssen Biotech, Inc. | Proteines comprenant des domaines de liaison a l'antigene cd3 et leurs utilisations |
BR112022023931A2 (pt) | 2020-05-27 | 2023-04-11 | Arialys Therapeutics Inc | Derivado de anticorpo nr1 anti-humano |
CN116529267A (zh) | 2020-06-04 | 2023-08-01 | 肯乔克蒂生物技术股份有限公司 | Abcg2外排泵-癌症抗原多特异性抗体及其相关组合物、试剂、试剂盒和方法 |
EP4171651A1 (fr) | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combinaison d'un conjugué anticorps-médicament et d'un inhibiteur de l'atm |
WO2021260583A1 (fr) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur de la dna-pk |
JP2023542065A (ja) | 2020-06-24 | 2023-10-05 | アストラゼネカ ユーケー リミテッド | 抗体-薬物複合物及びcdk9阻害剤の組み合わせ |
WO2021260582A1 (fr) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur d'aurora b |
CN116635082A (zh) | 2020-06-24 | 2023-08-22 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atr抑制剂的组合 |
EP4171527A1 (fr) | 2020-06-25 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de traitement et de diagnostic d'états pathologiques associés à un stress intense |
TW202216212A (zh) | 2020-07-17 | 2022-05-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物之製造方法 |
US20230293714A1 (en) | 2020-07-20 | 2023-09-21 | Daiichi Sankyo Company, Limited | Combination of anti-her2 antibody-drug conjugate with her dimerization inhibitor |
CA3190307A1 (fr) | 2020-07-29 | 2022-02-03 | Janssen Biotech, Inc. | Proteines comprenant des domaines de liaison a l'antigene hla-g et leurs utilisations |
RU2764216C1 (ru) * | 2020-08-10 | 2022-01-14 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Чувашский государственный университет имени И.Н. Ульянова" | Способ лечения гломерулонефритов с нефротическим синдромом рецидивирующего течения |
IL300588A (en) | 2020-08-12 | 2023-04-01 | Biond Biologics Ltd | Antibodies against ILT-2 and their use |
US20240009310A1 (en) | 2020-08-24 | 2024-01-11 | Charité - Universitätsmedizin Berlin | A CHIMERIC ANTIGEN RECEPTOR CONSTRUCT ENCODING A CHECKPOINT INHIBITORY MOLECULE AND AN IMMUNE STIMULATORY CYTOKINE AND CAR-EXPRESSING CELLS RECOGNIZING CD44v6 |
EP4199958A1 (fr) | 2020-08-24 | 2023-06-28 | Charité - Universitätsmedizin Berlin | Cellules exprimant le récepteur antigénique chimérique (car) reconnaissant l'ace |
EP4208259A2 (fr) | 2020-09-04 | 2023-07-12 | NovaRock Biotherapeutics, Ltd. | Anticorps anti-nectine-4 et leurs utilisations |
US20230340149A1 (en) | 2020-09-07 | 2023-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of treatment of inflammatory bowel diseases |
JP2023545359A (ja) | 2020-09-12 | 2023-10-30 | アストラゼネカ・ユーケイ・リミテッド | 抗her2抗体-薬物複合体治療のためのスコアリング方法 |
IL301883A (en) | 2020-10-05 | 2023-06-01 | Chiome Bioscience Inc | A drug to treat cancer |
BR112023006337A2 (pt) | 2020-10-09 | 2023-05-09 | Astrazeneca Uk Ltd | Produto farmacêutico, uso de um conjugado anticorpo anti-her2-fármaco ou um inibidor seletivo de parp1, e, método de tratamento do câncer |
UY39467A (es) | 2020-10-13 | 2022-04-29 | Janssen Biotech Inc | Inmunidad mediada por células t de bioingeniería, materiales y otros métodos para modular el grupo de diferenciación iv y / o viii |
EP4232064A1 (fr) | 2020-10-21 | 2023-08-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Fragments de sparc à terminaison c pour le traitement du cancer |
WO2022084915A1 (fr) | 2020-10-22 | 2022-04-28 | Janssen Biotech, Inc. | Protéines comprenant des domaines de liaison à l'antigène du ligand 3 de type delta et leurs utilisations |
WO2022097090A1 (fr) | 2020-11-05 | 2022-05-12 | Novartis Ag | Schéma posologique et polythérapies avec des anticorps multispécifiques ciblant un antigène de maturation des lymphocytes b et des inhibiteurs de gamma secrétase |
KR20230113564A (ko) | 2020-11-06 | 2023-07-31 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 다낭성 난소 증후군(pcos)의 진단 및 치료 방법 |
TW202227140A (zh) | 2020-11-11 | 2022-07-16 | 日商第一三共股份有限公司 | 抗體-藥物結合物及抗SIRPα抗體之組合 |
TW202233249A (zh) | 2020-11-12 | 2022-09-01 | 日商第一三共股份有限公司 | 藉由投與抗b7-h3抗體-藥物結合物之間皮瘤之治療 |
AR124063A1 (es) | 2020-11-16 | 2023-02-08 | Astellas Pharma Inc | Anticuerpo biespecífico anti-tspan8 / anti-cd3 y anticuerpo anti-tspan8 |
WO2022112469A1 (fr) | 2020-11-27 | 2022-06-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés de diagnostic et de surveillance de la nécrolyse épidermique toxique |
WO2022115120A1 (fr) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Polythérapie comprenant un anticorps anti-cd19 et le parsaclisib |
JP2023551519A (ja) | 2020-11-30 | 2023-12-08 | インサイト・コーポレイション | 抗cd19抗体とパルサクリシブの組み合わせ療法 |
WO2022124247A1 (fr) | 2020-12-09 | 2022-06-16 | 国立大学法人 東京医科歯科大学 | Agent de prévention ou de traitement de la dégénérescence lobaire fronto-temporale |
EP4271384A1 (fr) | 2020-12-29 | 2023-11-08 | Incyte Corporation | Polythérapie comprenant des inhibiteurs a2a/a2b, des inhibiteurs pd-1/pd-l1 et des anticorps anti-cd73 |
MX2023008261A (es) | 2021-01-13 | 2023-09-12 | Memorial Sloan Kettering Cancer Center | Conjugado de anticuerpo-derivado de pirrolobenzodiazepina. |
US20240115721A1 (en) | 2021-01-13 | 2024-04-11 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
WO2022153212A1 (fr) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Anticorps neutralisant le sars-cov-2 |
KR20230137393A (ko) | 2021-01-28 | 2023-10-04 | 얀센 바이오테크 인코포레이티드 | Psma 결합 단백질 및 이의 용도 |
JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗cd73及び抗entpd2抗体のための投与方式並びにその使用 |
TW202241454A (zh) | 2021-02-01 | 2022-11-01 | 日商第一三共股份有限公司 | 抗體-免疫賦活化劑共軛物之新穎製造方法 |
AU2022219681A1 (en) | 2021-02-11 | 2023-09-21 | Nectin Therapeutics Ltd. | Antibodies against cd112r and uses thereof |
CN116848136A (zh) | 2021-02-12 | 2023-10-03 | 勃林格殷格翰国际有限公司 | 补体c3抗原结合蛋白 |
US20220378929A1 (en) | 2021-02-25 | 2022-12-01 | MediBoston Limted | Anti-her2 antibody-drug conjugates and uses thereof |
CN117425674A (zh) | 2021-03-02 | 2024-01-19 | 丹娜法伯癌症研究院 | 治疗红细胞疾患的方法 |
CN116917341A (zh) | 2021-03-12 | 2023-10-20 | 第一三共株式会社 | 糖链以及包含糖链的医药品的制造方法 |
WO2022189632A1 (fr) | 2021-03-12 | 2022-09-15 | Fibrosys S.R.L. | Anticorps monoclonaux pour le traitement d'infections virales |
TW202304986A (zh) | 2021-03-24 | 2023-02-01 | 美商健生生物科技公司 | 靶向cd22及cd79b的抗體 |
IL307168A (en) | 2021-03-26 | 2023-11-01 | Janssen Biotech Inc | Humanized antibodies against paired helical strands of TAU protein and their uses |
WO2022218998A1 (fr) | 2021-04-13 | 2022-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes de traitement d'une infection par le virus de l'hépatite b et d |
JP2024513921A (ja) | 2021-04-14 | 2024-03-27 | ヴィラリス・セラピューティクス・インコーポレイテッド | 抗cd122抗体及びその使用 |
IL307744A (en) | 2021-04-22 | 2023-12-01 | Astellas Pharma Inc | Anti-CLDN4/anti-CD137 bispecific antibody |
WO2022261183A2 (fr) | 2021-06-08 | 2022-12-15 | Dana-Farber Cancer Institute, Inc. | Compositions et procédés de traitement et/ou d'identification d'un agent pour le traitement de cancers intestinaux |
CN113361141B (zh) * | 2021-07-11 | 2022-02-18 | 西南石油大学 | 一种dna图谱算法的改进试验方法 |
PE20240727A1 (es) | 2021-08-27 | 2024-04-15 | Janssen Biotech Inc | Anticuerpos anti-psma y usos de estos |
CA3231632A1 (fr) | 2021-09-15 | 2023-03-23 | Daiichi Sankyo Company, Limited | Conjugue anticorps-medicament destine a etre utilise dans des methodes de traitement de cancer resistant a la chimiotherapie |
WO2023041744A1 (fr) | 2021-09-17 | 2023-03-23 | Institut Curie | Inhibiteurs de bet pour le traitement du cancer à déficit en bap1 |
WO2023046322A1 (fr) | 2021-09-24 | 2023-03-30 | Janssen Pharmaceutica Nv | Protéines comprenant des domaines de liaison à cd20, et leurs utilisations |
WO2023052541A1 (fr) | 2021-09-30 | 2023-04-06 | Imcheck Therapeutics | Combinaison d'un anticorps d'activation anti-btn3a et d'un agoniste il-2 en vue d'une utilisation en thérapie |
CA3235358A1 (en) | 2021-10-18 | 2023-04-27 | Daiichi Sankyo Company, Limited | Anti-cd37 antibody-drug conjugate |
AU2022378932A1 (en) | 2021-10-27 | 2024-05-02 | Assistance Publique Hopitaux De Marseille | Butyrophilin (btn) 3a activating antibodies for use in methods for treating infectious disorders |
EP4177266A1 (fr) | 2021-11-05 | 2023-05-10 | Katholieke Universiteit Leuven | Neutralisation d'anticorps humains anti-sars-cov-2 |
TW202329936A (zh) | 2021-11-18 | 2023-08-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物與parp1選擇性抑制劑之組合 |
WO2023089032A1 (fr) | 2021-11-19 | 2023-05-25 | Institut Curie | Méthodes de traitement du cancer hrd et du cancer associé au brca |
WO2023097119A2 (fr) | 2021-11-29 | 2023-06-01 | Dana-Farber Cancer Institute, Inc. | Méthodes et compositions pour moduler riok2 |
WO2023099763A1 (fr) | 2021-12-03 | 2023-06-08 | Institut Curie | Inhibiteurs de sirt6 destinés à être utilisés dans le traitement du cancer hrd résistant |
WO2023105528A1 (fr) | 2021-12-12 | 2023-06-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anticorps spécifiques de ceacam1 |
TW202334231A (zh) | 2021-12-22 | 2023-09-01 | 德商莫菲西斯公司 | 抗cd19抗體療法的治療範例 |
TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
WO2023126822A1 (fr) | 2021-12-28 | 2023-07-06 | Astrazeneca Uk Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur de rasg12c |
WO2023152581A1 (fr) | 2022-02-09 | 2023-08-17 | Janssen Biotech, Inc. | Méthode de traitement du cancer à l'aide d'un anticorps anti-psmaxcd3 |
WO2023166081A1 (fr) | 2022-03-02 | 2023-09-07 | Heidelberg Immunotherapeutics Gmbh | Vaccin comprenant un anticorps ou une protéine de fusion contenant fc comprenant une partie fc d'un anticorps |
WO2023175614A1 (fr) | 2022-03-15 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Anticorps anti-protéine liée au tnfr induite par glucocorticoïdes (gitr) et leurs utilisations |
WO2023175483A1 (fr) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | Procédé de notation pour une thérapie par conjugué anticorps-médicament anti-trop2 |
WO2023209591A1 (fr) | 2022-04-27 | 2023-11-02 | Daiichi Sankyo Company, Limited | Combinaison d'un conjugué anticorps-médicament avec un inhibiteur de l'ezh1 et/ou de l'ezh2 |
WO2023218378A1 (fr) | 2022-05-11 | 2023-11-16 | Daiichi Sankyo Company, Limited | Association combinant un anticorps spécifique d'un antigène tumoral et un inhibiteur de cd47 |
WO2023228095A1 (fr) | 2022-05-24 | 2023-11-30 | Daiichi Sankyo Company, Limited | Schéma posologique d'un conjugué anticorps anti-cdh6-médicament |
WO2024013723A1 (fr) | 2022-07-15 | 2024-01-18 | Pheon Therapeutics Ltd | Conjugués anticorps-médicament qui se lient à cdcp1 et leurs utilisations |
WO2024023750A1 (fr) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Association d'un conjugué anticorps-médicament et d'un inhibiteur de point de contrôle bispécifique |
WO2024072893A1 (fr) | 2022-09-28 | 2024-04-04 | Incyte Corporation | Anticorps bispécifiques dirigés contre pd-1/lag-3 et leurs utilisations |
WO2024074498A1 (fr) | 2022-10-04 | 2024-04-11 | Imcheck Therapeutics | Combinaison d'un anticorps d'activation de btn3a, d'un inhibiteur de bcl2 et d'un agent d'hypométhylation destinée à être utilisée dans le traitement du cancer |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
JPS6033453B2 (ja) * | 1978-08-17 | 1985-08-02 | 富士電機株式会社 | 魚切断加工自動化装置 |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
JPS6014678A (ja) * | 1983-07-04 | 1985-01-25 | Taiheiyo Kogyo Kk | 電磁弁 |
GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
GB2188941B (en) * | 1986-04-14 | 1990-06-06 | Bayer Ag | Monoclonal antibodies recognizing human interleukin-2-receptor |
DK554986A (da) * | 1986-11-19 | 1988-07-18 | Novo Industri As | Human-human hybride cellelinier samt dermed producerede monoklonale cancerantistoffer |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
JP3121823B2 (ja) * | 1988-02-12 | 2001-01-09 | ビーティージー・インターナショナル・リミテッド | 抗体におけるまたは抗体に関する改良 |
WO1989009622A1 (fr) * | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Anticorps chimeriques specifiques au recepteur il-2 |
JP5598363B2 (ja) | 2011-02-15 | 2014-10-01 | ソニー株式会社 | 記憶装置およびその動作方法 |
-
1989
- 1989-11-27 IL IL162181A patent/IL162181A/en not_active IP Right Cessation
- 1989-12-27 IL IL92904A patent/IL92904A0/xx not_active IP Right Cessation
- 1989-12-28 EP EP04076438.3A patent/EP1491556B1/fr not_active Expired - Lifetime
- 1989-12-28 DE DE04076439.1T patent/DE04076439T1/de active Pending
- 1989-12-28 AT AT90903576T patent/ATE133452T1/de active
- 1989-12-28 MC MC@@@@D patent/MC2146A1/fr unknown
- 1989-12-28 YU YU248989A patent/YU48700B/sh unknown
- 1989-12-28 ES ES98204240.0T patent/ES2492815T3/es not_active Expired - Lifetime
- 1989-12-28 AU AU51532/90A patent/AU647383B2/en not_active Expired
- 1989-12-28 ES ES95105609T patent/ES2136760T3/es not_active Expired - Lifetime
- 1989-12-28 JP JP2503677A patent/JP2828340B2/ja not_active Ceased
- 1989-12-28 IE IE20000331A patent/IE20000331A1/en unknown
- 1989-12-28 RU SU4895847/13A patent/RU2126046C1/ru active
- 1989-12-28 CA CA002006865A patent/CA2006865C/fr not_active Expired - Lifetime
- 1989-12-28 DE DE122005000057C patent/DE122005000057I2/de active Active
- 1989-12-28 DE DE19975047C patent/DE19975047I2/de active Active
- 1989-12-28 DE DE2000175038 patent/DE10075038I2/de active Active
- 1989-12-28 EP EP90903576A patent/EP0451216B9/fr not_active Expired - Lifetime
- 1989-12-28 DE DE122009000071C patent/DE122009000071I1/de active Pending
- 1989-12-28 EP EP04076439.1A patent/EP1477497B1/fr not_active Expired - Lifetime
- 1989-12-28 KR KR1019900701939A patent/KR0178385B1/ko not_active IP Right Cessation
- 1989-12-28 DE DE200712000037 patent/DE122007000037I1/de active Pending
- 1989-12-28 DE DE68925536A patent/DE68925536D1/de not_active Expired - Lifetime
- 1989-12-28 CA CA002328851A patent/CA2328851C/fr not_active Expired - Lifetime
- 1989-12-28 DE DE122005000007C patent/DE122005000007I2/de active Active
- 1989-12-28 SI SI8912489A patent/SI8912489B/sl unknown
- 1989-12-28 DE DE04076438.3T patent/DE04076438T1/de active Pending
- 1989-12-28 DE DE68929061T patent/DE68929061T2/de not_active Expired - Lifetime
- 1989-12-28 ES ES04076438.3T patent/ES2440825T3/es not_active Expired - Lifetime
- 1989-12-28 WO PCT/US1989/005857 patent/WO1990007861A1/fr active IP Right Grant
- 1989-12-28 DE DE2000175005 patent/DE10075005I2/de active Active
- 1989-12-28 ES ES90903576T patent/ES2081974T5/es not_active Expired - Lifetime
- 1989-12-28 DE DE1989625536 patent/DE122006000036I1/de active Pending
- 1989-12-28 AT AT95105609T patent/ATE183753T1/de not_active IP Right Cessation
- 1989-12-28 PT PT92758A patent/PT92758B/pt active IP Right Grant
- 1989-12-28 DE DE68925536T patent/DE68925536T3/de not_active Expired - Lifetime
- 1989-12-28 CN CN89109618A patent/CN1057013C/zh not_active Expired - Lifetime
- 1989-12-28 ES ES04076439.1T patent/ES2523810T3/es not_active Expired - Lifetime
- 1989-12-28 ZA ZA899956A patent/ZA899956B/xx unknown
- 1989-12-28 EP EP10185689A patent/EP2341080A1/fr not_active Withdrawn
- 1989-12-28 EP EP95105609A patent/EP0682040B1/fr not_active Revoked
- 1989-12-28 EP EP98204240.0A patent/EP0939127B1/fr not_active Expired - Lifetime
- 1989-12-28 DE DE98204240.0T patent/DE98204240T1/de active Pending
-
1990
- 1990-01-04 NZ NZ231984A patent/NZ231984A/en unknown
- 1990-01-04 NZ NZ314793A patent/NZ314793A/xx unknown
- 1990-01-17 DD DD90337159A patent/DD296964A5/de unknown
-
1991
- 1991-05-20 FI FI912436A patent/FI108797B/fi active Protection Beyond IP Right Term
- 1991-06-19 NO NO19912385A patent/NO310473B1/no not_active IP Right Cessation
- 1991-06-19 DK DK119191A patent/DK119191A/da not_active Application Discontinuation
- 1991-12-31 CZ CS914186A patent/CZ418691A3/cs unknown
-
1992
- 1992-01-20 BG BG95784A patent/BG61095B2/xx unknown
- 1992-09-26 HR HRP-2489/89A patent/HRP920500B1/xx not_active IP Right Cessation
-
1995
- 1995-06-16 HU HU95P/P00236P patent/HU211174A9/hu active Protection Beyond IP Right Term
-
1996
- 1996-04-13 SG SG1996007855A patent/SG78258A1/en unknown
-
1998
- 1998-01-12 JP JP00433498A patent/JP3604058B2/ja not_active Expired - Lifetime
- 1998-07-16 DK DK199800941A patent/DK174317B1/da not_active IP Right Cessation
- 1998-12-28 HK HK98115967A patent/HK1014718A1/xx not_active IP Right Cessation
-
1999
- 1999-07-02 LU LU90411C patent/LU90411I2/fr unknown
- 1999-07-14 NL NL990020C patent/NL990020I2/nl unknown
-
2000
- 2000-02-11 NL NL300005C patent/NL300005I2/nl unknown
- 2000-02-11 LU LU90528C patent/LU90528I2/fr unknown
- 2000-11-03 NL NL300023C patent/NL300023I2/nl unknown
- 2000-11-09 LU LU90676C patent/LU90676I2/fr unknown
-
2001
- 2001-12-17 NO NO2001024C patent/NO2001024I1/no unknown
- 2001-12-17 NO NO2001026C patent/NO2001026I2/no unknown
- 2001-12-17 NO NO2001025C patent/NO2001025I2/no unknown
-
2003
- 2003-01-20 JP JP2003011706A patent/JP2003245091A/ja not_active Withdrawn
- 2003-01-20 JP JP2003011705A patent/JP2003245090A/ja not_active Withdrawn
-
2005
- 2005-02-04 LU LU91139C patent/LU91139I2/fr unknown
- 2005-02-10 NL NL300173C patent/NL300173I2/nl unknown
- 2005-02-18 NO NO2005005C patent/NO2005005I2/no unknown
- 2005-12-02 LU LU91208C patent/LU91208I2/fr unknown
- 2005-12-07 NO NO2005026C patent/NO2005026I2/no unknown
- 2005-12-12 NL NL300213C patent/NL300213I2/nl unknown
-
2006
- 2006-08-07 NL NL300239C patent/NL300239I2/nl unknown
- 2006-08-07 NO NO2006009C patent/NO2006009I2/no unknown
- 2006-08-07 LU LU91272C patent/LU91272I2/fr unknown
-
2007
- 2007-03-02 JP JP2007053539A patent/JP2007145863A/ja not_active Withdrawn
- 2007-04-11 LU LU91333C patent/LU91333I2/fr unknown
- 2007-04-18 NL NL300279C patent/NL300279I2/nl unknown
- 2007-04-18 NO NO2007006C patent/NO2007006I2/no unknown
-
2009
- 2009-04-21 JP JP2009103471A patent/JP2009165488A/ja not_active Withdrawn
- 2009-11-12 NO NO2009026C patent/NO2009026I1/no unknown
- 2009-11-19 NL NL300426C patent/NL300426I1/nl unknown
- 2009-12-09 LU LU91627C patent/LU91627I2/fr unknown
-
2014
- 2014-09-17 FR FR14C0070C patent/FR14C0070I1/fr active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO310473B1 (no) | Fremgangsmåte for fremstilling av humanisert immunoglobulin, polynukleotid som koder for nevnte immunoglobulin og cellelinjesom er transfektert med nevnte polynukleotid | |
US5585089A (en) | Humanized immunoglobulins | |
US20080160018A1 (en) | Humanized immunoglobulins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: TRASTUZUMAB ELLER FARMASOEYTISKE AKSEPTABLE SALTER DERAV; NAT. REG. NO/DATE: NO , EU/1/00/14 20000928; FIRST REG. NO/DATE: EP , EU/1/00/14 20000828 Spc suppl protection certif: 2001024 Filing date: 20011217 Extension date: 20141228 Effective date: 20031229 |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: XOLAIR, 75 MG OG 150 MG, PULVER OG VAESKE TIL INJEKSJONSVAESKE, OPPLOESNING; NAT. REG. NO/DATE: EU/1/05/319/00-002/NO 20051025; FIRST REG. NO/DATE: EU , EU/1/05/319/00-002 20051025 Spc suppl protection certif: 2005026 Filing date: 20051207 Extension date: 20141228 |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: TYSABRI; NAT. REG. NO/DATE: EU106346NO 20060627; FIRST REG. NO/DATE: EU , EU106346 20060627 Spc suppl protection certif: 2006009 Filing date: 20060807 Extension date: 20141228 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: DACLIZUMAB; NAT. REG. NO/DATE: NO , 97-3585 19991126; FIRST REG. NO/DATE: EP , EU/1/99/09 19990226 Spc suppl protection certif: 2001026 Filing date: 20011217 Extension date: 20130303 |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: LUCENTIS 10 MG/ML INJEKSJONSVAESKE, OPPLOSNING "NOVARTIS EUROPHARM" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU106374001NO 20070207; FIRST REG. NO/DATE: LI , 57664 20060825 Spc suppl protection certif: 2007006 Filing date: 20070418 Extension date: 20141228 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: AVASTIN, 25 MG/ML, KONSENTRAT TIL OPPLOSNING FOR INFUSJON, INTRAVENOS ANVENDELSE; NAT. REG. NO/DATE: EU/1/04/300/001/NO-002/NO 20050118; FIRST REG. NO/DATE: EU , EU/1/04/300/001-002 20050112 Spc suppl protection certif: 2005005 Filing date: 20050218 Extension date: 20141228 Free format text: PRODUCT NAME: XOLAIR, 75 MG OG 150 MG, PULVER OG VAESKE TIL INJEKSJONSVAESKE, OPPLOESNING; NAT. REG. NO/DATE: EU/1/05/319/00-002/NO 20051025; FIRST REG. NO/DATE: EU , EU/1/05/319/00-002 20051025 Spc suppl protection certif: 2005026 Filing date: 20051207 Extension date: 20141228 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: LUCENTIS 10 MG/ML INJEKSJONSVAESKE, OPPLOSNING "NOVARTIS EUROPHARM" - 1 HETTEGLASS; NAT. REG. NO/DATE: EU106374001NO 20070207; FIRST REG. NO/DATE: LI , 57664 20060825 Spc suppl protection certif: 2007006 Filing date: 20070418 Extension date: 20141228 Free format text: PRODUCT NAME: TYSABRI; NAT. REG. NO/DATE: EU106346NO 20060627; FIRST REG. NO/DATE: EU , EU106346 20060627 Spc suppl protection certif: 2006009 Filing date: 20060807 Extension date: 20141228 |
|
MK1K | Patent expired | ||
SPCX | Expiry of an spc |
Spc suppl protection certif: 2005005 Effective date: 20141228 Spc suppl protection certif: 2001024 Effective date: 20141228 Spc suppl protection certif: 2006009 Effective date: 20141228 Spc suppl protection certif: 2007006 Effective date: 20141228 Spc suppl protection certif: 2005026 Effective date: 20141228 |